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Abstract 
 
N. meningitidis, is a common commensal of the human upper respiratory tract 
and a leading cause of bacterial meningitis and septicemia worldwide. The 
classical pathway of complement (C) is essential for both naturally acquired 
and vaccine induced immunity against N. meningitidis. Qualitative and/or 
quantitative differences in anti-meningococcal antibodies (Abs) in serum is 
one reason for variations in C-dependent bactericidal Ab activity among 
individuals.  I showed that IgG isolated from select individuals could block 
killing of group B meningococci by Abs that were otherwise bactericidal. 
Ligand overlay immunoblots revealed that these blocking IgG Abs were 
directed against a meningococcal antigen called H.8, Killing of meningococci 
in reactions containing bactericidal mAbs and human blocking Abs was 
restored when blocking Ab binding to meningococci was inhibited (or 
competed for) using either synthetic peptides corresponding to H.8 or a non-
blocking mAb against H.8.  Further, genetic deletion of H.8 from target 
organisms abrogated blocking. The Fc region of the blocking IgG was 
required for blocking because F(ab)2 fragments alone generated by pepsin 
treatment were ineffective. Blocking required IgG glycosylation; 
deglycosylation of blocking IgG with peptide:N-glycanase (PNGase) 
eliminated blocking.  C4 deposition mediated by a bactericidal mAb directed 
against a meningococcal vaccine candidate, called factor H-binding protein 
(fHbp), was reduced by blocking Ab. Anti-fHbp-mediated C4 deposition was 
unaffected, however, by deglycosylated blocking IgG. Although preliminary, 
our data suggests blocking of serum bactericidal activity by human anti-H.8  
           xii 
 
blocking antibody may require mannan-binding lectin (MBL), which itself is a 
complement activator. Also, whether MBL recruits a complement inhibitor(s) 
that facilitates blocking remains to be determined. In conclusion, we have 
identified H.8 as a meningococcal target for novel blocking antibodies that are 
commonly found in human serum. Blocking Ab may reduce the efficacy of 
meningococcal vaccines. We propose that outer membrane vesicle-containing 
meningococcal vaccines may be more efficacious if purged of subversive 
immunogens such as H.8. 
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Introduction 
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1.1 Bacteriology  
Neisseria meningitidis is one of the leading causes of meningitis and 
septicemia worldwide. It is commonly found as a commensal organism in the 
human upper respiratory tract.  N. meningitdis is a gram-negative diplococcus 
that belongs to the family Neisseriaceae (1).  It has a genome size of 2.0-2.2 
million base pairs (approx. 2000 genes). The complete genome sequences of 
meningococcal strains Z2491 (NC_003116.1), MC58 (NC_003112.2), FAM18 
(NC_008767.1) and 053442 (NC_010120.1) and incomplete sequences of 
strains α153 (GenBank: AM889137.1) and α275 (GenBank: AM889138.1) are 
available (2-6).  Structurally, meningococcal cell walls are similar to those of 
most gram-negative organisms (Figure 1.1). The cell wall is comprised of 
outer and inner membranes with an intervening periplasmic space. The outer 
membrane components include outer membrane proteins and 
lipopolysaccharide (LPS) and may also include one of several different 
capsular polysaccharides.  The LPS of N. meningitidis does not possess O 
antigenic repeating units that characterizes the LPS of most gram-negative 
bacteria and is therefore frequently referred to as lipooligosaccharide (LOS).  
Akin to LPS, LOS also possesses endotoxic properties and is linked with 
bacterial pathogenesis (7). 
 
1.2 Epidemiology 
Meningococcal disease is a major public health problem in most parts 
of the world because of the rapid onset of disease (both meningitis and 
septicemia), high mortality and serious sequelae.  N. meningitidis has been 
classified into 13 different serogroups based upon the chemical composition 
2
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Figure 1.1: Structure of N. meningitidis membrane. 
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of its capsular polysaccharide.  Of these, serogroups A, B, C, W-135 and Y 
are responsible for most cases of epidemic meningitis (Figure 1.2). The 
incidence of meningococcal disease is highest in children under 2 years of 
age; a second peak of incidence occurs in adolescents (14-19 years) and 
young adults who live in college dormitories and military barracks (Figure 1.3).  
Epidemics caused by the different serogroups of N. meningitidis are localized 
to distinct geographic locations (Figure 1.4).  The African meningitis belt 
(located in sub-Saharan Africa stretching from Senegal to Ethiopia) has been 
one of the most severly striken areas in recent times (8, 9), where recurring 
epidemics of serogroup A N. meningitidis have been prevalent.  The high 
prevalence of meningitis in this region is not fully understood; climatic factors 
(dusty winds in dry seasons when incidence of infection is higher) (10), low 
levels of natural immunity in the population and perhaps, certain 
characteristics unique to the pathogen have been cited as reasons (11). 
Serogroup C epidemics (12) and more recently, a serogroup W-135 epidemic 
was reported in pilgrims to the Hajj (13).  Serogroup C epidemics are common 
in many parts of the world, including Europe; currently, serogroup Y strains 
are responsible for about a third of cases of meningococcal disease in the 
United States.  Serogroup X epidemics are emerging as the cause of 
epidemics in certain African countries including Nigeria, Togo and western 
Kenya.  In Europe and the majority of the developed world, serogroup B 
disease is most prevalent.  Endemic disease incidence averages about 1.1 
per 100,000, which can rise to as high as 1 in 100 per 100,000 during 
epidemics.  In Australia, the incidence of meningococcal disease averages 
about 1.5-4 per 100,000; most disease is caused by serogroups B and C.   In 
4
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Figure 1.2: Composition of the capsular polysaccharides of the major disease caus-
ing serogroups of N. meningitidis.
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Figure 1.3: Age related incidence of meningococcal disease in the United States 
prevelance of serum bactericidal activity against three pathogenic strains of N. 
meningitidis (reproduced from: Goldschneider I et al, J Exp Med. 1969 Jun 1;129 
(6):1307-26) .Number of cases/100,000 age-specific population (black triangle), 1965; 
number of cases/100,000 age-specific population, 1966 (white triangle); [-----] age distri-
bution of 72 cases admitted to Los Angeles Children's Hospital 1944-1953; percent of 
sera in each age group having a bactericidal titer of 1:4 or greater against  meningococcal 
strains AI (red line), BII, (blue line) and CII (green line). Sera from 282 children (at least 
20 in each age group) and 567 army recruits (ages 19 to 26 yr) were tested in the pres-
ence of exogenous ‘human’ complement. Each point in the figure represents the inci-
dence of disease or prevalence of bactericidal activity among subjects in the age range 
encompassed by it and the previous point (e.g., 2.5% of children 6-12 months of age had 
serum bactericidal activity against meningococcal strain A1.  .
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New Zealand the incidence of serogroup B infections rose to 17.4 per 100,000 
in 2001, following the epidemic of serogroup B disease that began in the 
1990s.  Outbreaks of serogroup B disease epidemics have also been reported 
in Norway (14), Brazil (15), Cuba (16) and Chile (17).  Epidemics of serogroup 
B meningococcal disease in these countries have led to efforts to produce 
“tailor-made” outer membrane vesicle vaccines (discussed below).  Lack of an 
effective vaccine against serogroup B disease that can be used universally 
has made prevention of this disease difficult.  
 
1.3 Epidemiology of meningococcal meningitis in the United States  
The epidemiology of meningococcal disease in the United States is 
highly dynamic.  The annual incidence of meningococcal meningitis in the US 
overall has remained at 0.5 to 1.5 cases per 100,000 since the Second World 
War.  However, the incidence of meningitis has shown cyclical variations over 
the last 30 years.  Following a recent peak in incidence in the mid 1990s, the 
incidence rate decreased to a low of 0.35 per 100,000 in 2007, which followed 
the licensure of a quadrivalent meningococcal conjugate vaccine (MCV4) in 
2000.  MCV4 contains capsular polysaccharide antigens of N. meningitidis 
serogroups A, C, Y, and W-135 strains individually conjugated to diphtheria 
toxoid protein.  As expected, MCV4 vaccine has not affected the incidence of 
serogroup B disease.  In the U.S between 1998 and 2007, the highest 
incidence of serogroup B meningococcal disease has been recorded in 
infants (<1 year, 5.4/100,000), toddlers (1-4 years, 1.04/100,000), young 
adults (15-24years, 0.78/100,000) and senior citizens (>65 years, 
0.69/100,000).  
8
  
 
1.4 Pathogenesis and route of infection 
1.4.1 Initial Colonization: Because N. meningitidis commonly colonizes the 
human upper respiratory tract it is transmitted from person-to-person by 
droplets. In the nasopharynx, meningococci are believed to interact with CD46 
or membrane cofactor protein (MCP) through bacterial type IV Pili (TFP) (18). 
The role of CD46 in facilitating adherence of meningococci to eukaryotic cells 
remains controversial because CD46 is believed to be localized primarily at 
the basolateral surfaces of polarized cells.  TFP mediated adhesion of 
meningococci to the epithelial surface of the nasopharynx occurs in two 
sequential steps: 1) bacteria attach to the apical surface of the host cells and 
2) bacteria divide and form a monolayer on the apical surface.  Monolayer 
formation is aided by bacteria-bacteria interactions that is mediated by pilin 
(19, 20).  
1.4.2 Invasion of the epithelial layer and transcytosis: Adherence of 
meningococci to epithelial cell is followed by bacteria-induced formation of 
local elongation of microvilli around the bacteria that leads to engulfment and 
internalization (21, 22). Several hours after interaction of meningococci with 
epithelial cells, bacteria disperse on the epithelial surface and form tight 
contacts with the cells, a process called diffuse adhesion (22, 23).  This 
process is coordinated by regulated expression of several bacterial genes that 
contain the promoter element called CREN (contact regulatory element of 
Neisseria) (24).   CrgA, a LysR-type transcriptional regulator involved in the 
intimate adhesion of N. meningitidis to target human epithelial cells, is one 
such protein.  Upregulaion of CrgA results in downregulation of sia and pilE 
9
  
gene expression, thereby inhibiting synthesis of the capsule and pilin E 
respectively.  These two structures inhibit intimate bacterial adhesion and 
invasion of host cells (24, 25).  Meningococcal outer membrane opacity 
proteins, Opa and Opc, are also involved in intimate adhesion of 
meningococci to epithelial cells (26-28). The Opa family of proteins contains 8 
transmembrane beta-barrel strands and four surface exposed loops. The first 
three loops are antigenically variable.  Because meningococci possess up to 
4 opa genes, a single bacterium can express more than one Opa protein 
simultaneously (26).  Differential Opa expression may also determine tissue 
tropism (29, 30).  Opa proteins bind the CD66/CEACAM family of proteins on 
host cells.  Different members of the CD66 family of proteins are expressed 
on different host cells, which determines the cell specificity of the interaction 
of meningococci that express a certain type of Opa(s) (31). Opc shares weak 
amino acid homology with Opa but is structurally different (32). One of the 
Opc proteins, OpcA, adopts a 10-stranded beta-barrel structure with extensive 
loop regions that protrude above the predicted surface of the membrane (33). 
Once it enters the blood stream, meningococci may traverse the blood-brain 
barrier to cause meningitis or disseminate to various organs to cause 
meningococcemia, or both.  Vitronectin forms a bridge between Opc protein 
and αυβ 3 integrins on the endothelial cell surface independent of pili or Opa 
(34-38). 
 
1.5 Clinical manifestations 
  In most instances pharyngeal acquisition of N. meningitidis results in 
asymptomatic carriage.  Colonizing stains spread from individual to individual 
10
  
via respiratory droplets.  The carriage rate and disease rate of meningococci 
are not directly proportional (39).  At any time, about 10% of the population at 
large are colonized with meningococci.  Carriage rates are low in infants and 
children but higher in teenagers and young adults (40, 41).  Progression from 
carriage to disease is not fully understood, but is likely determined both by 
host and bacterial factors.  Typically, disease when it occurs, takes place 10 
days following colonization of a susceptible individual (42).  
Meningococcal disease may present either as meningitis (infection and 
inflammation of the meninges) or bloodborne infection accompanied by 
septicemia (meningococcemia).  Sometimes, menigococcal bacteremia 
occurs without symptoms but may progess to meningitis or septicemia.  Of all 
cases of meningococcal disease, meningitis alone occurs in 30-50% and 
results in a 5% mortality; septicemia, without meningitis, occurs 7-10% of the 
time and results in a higher (5-40%) mortality.   Meningitis and sepsis occur 
together in ~40% of cases (43-45).  Patients with meningitis may have one or 
more of the following symptoms and signs: headache, fever, vomiting, 
photophobia, stiff neck (nuchal rigidity) and a positive Kernig’s or Brudzinski’s 
sign.  Patients with meningococcemia may present with fever, purpuric rash, 
headache, flu-like symptoms, vomitting and abdominal pain.  
 
1.6 Principles of treatment 
 Early diagnosis and treatment is essential in managing meningococcal 
disease.  Delay in the initiation of treatment is associated with adverse 
outcomes including death.  Third-generation cephalosporins currently are the 
mainstay of treatment.  Prevention of disease in close contacts of the index 
11
  
case is important; individuals living in the same household are at higher risk 
for developing disease in the first week following diagnosis of the primary 
case (46) and chemoprophylaxis of close contacts is recommended. It should 
be noted that resistance of meningococci to quinolones, one of the agents 
used in chemoprophylaxis, has been reported. 
 
1.7 Vaccines against meningococcal disease 
Most cases of meningococcal disease are vaccine-preventable.  
Several different vaccine formulations against meningococcal disease have 
been developed and are discussed below. 
1.7.1 Capsular polysaccharide-based vaccines 
A. Unconjugated capsular polysaccharide vaccines:  Groups A and C 
polysaccharides were used as vaccines in the 1960s (47).  A quadrivalent 
purified polysaccharide vaccine that provided protection against groups A, C, 
W-135 and Y was licensed for use in the U.S in 1981 (48).  With the exception 
of the group A polysaccharide, this vaccine is poorly immunogenic in children 
< 2years of age. Capsular polysaccharides are T cell-independent antigens 
and as a result provide only short-lived immunity.  Repeated doses of 
polysaccharide vaccine may be required every 3-5 years because the immune 
B cell pool becomes depleted (49).  Furthermore, repeated doses of purified 
polysaccharide vaccines may induce antibody hyporesponsiveness due to 
tolerance.    
B. Polysaccharide-Protein conjugate vaccines:  To circumvent the 
limitation of purified capsular vaccines, several protein-polysaccharide 
conjugate vaccines have been developed.  Serogroup C polysaccharide 
12
  
conjugate vaccine (MenC) was first introduced in the United Kingdom in 1999 
in response to an epidemic of serogoup C disease, which resulted in 
substantial reduction in the number of disease cases (50) and carriage rates 
(51, 52).  Although, MenC administered at 2, 3 and 4 months of age was 
effective in providing protection up to 1 year of age, significant protection did 
not extend beyond one year (53).  The revised schedule in the U.K now 
recommends doses at 3 and 4 months, followed by a booster dose of Men C 
vaccine at 12 months.  Because typical symptoms of meningococcal infection 
manifest 24-72 h following invasion (54), progression of disease cannot be 
countered in time by a memory response (to the infection) that had been 
initiated by a conjugate vaccine (55).  Such protection requires significant 
levels of circulating antibodies that usually are not induced following 
vaccination in infancy because of the low survival rate of plasma cells in the 
first year of life (56).    
In 2000, a tetravalent polysaccharide vaccine conjugated to diphtheria 
toxoid (Menactra, or MCV4; Sanofi-Pasteur) was licensed in the U.S for use in 
people between the ages of 2 and 55 years.  Serogroup Y had accounted for 
37% of all meningococcal disease in USA between 1997 and 2002) (48). 
MCV4 is now universally recommended for college freshmen, travelers to 
meningococcal disease–endemic areas, military recruits and persons with 
immune deficiencies that diminish antibody production or compromise the 
complement system.  Again, the immunogenicity of this vaccine in infants is 
poor.  A second polysaccharide conjugate vaccine (Menveo; Novartis) 
conjugated to CRM197 (a mutant diphtheria toxin) was recently licensed for 
use in the U.S (57).  Presently, a combined vaccine comprising Haemophilus 
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influenzae type B and meningococcal C and Y capsules, each conjugated to 
tetanus toxoid, is undergoing clinical trials (58).  A conjugate vaccine 
(MenAfriVac) against serogroup A, which is a major cause of meningococcal 
disease in sub-Saharan Africa, is being developed by the Serum institute of 
India and is currently undergoing evaluation in Africa and India (59).  
 
1.8 Vaccines against Serogroup B N. meningitidis. 
There is no licensed polysaccharide based vaccine against serogroup 
B disease. The polysialic acid capsule (α [2,8]-linked polysialic acid) of 
serogroup B N. meningitidis is a poor immunogen because it mimics certain 
sialic acid containing glycoproteins on mammalian cells and tissues (self-
antigens).  This form of sialic acid is found as a component of neural cell 
adhesion molecule (N-CAM) which is involved in axonal growth and synaptic 
plasticity (60).  Purified serogroup B polysaccharide has been used as a 
vaccine in adult volunteers but it failed to elicit a significant anti-capsular 
antibody response (61).  To circumvent the problem of poor immunogenicity 
and concerns surrounding the production of auto antibodies following 
immunization with group B polysaccharide, alternative strategies have been 
attempted and are discussed below.  
1.8.1 Modified serogroup B capsule polysaccharide-protein conjugate:  
A group B polysaccharide vaccine has been designed whereby the N-acetyl 
group of polysialic acid was substituted with an N-propionyl group, followed by 
conjugation to tetanus toxoid (62).  This vaccine was highly immunogenic in 
mice.  Although also immunogenic, producing antibodies in human volunteers, 
no significant serogroup B specific serum bactericidal antibody activity was 
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elicited (63).  The generation of autoreactive antibodies against human 
polysialic acid residues may remain as a concern with these serogroup B 
vaccines (64) although no evidence of binding or deleterious effects of these 
potential auto-reactive antibodies to human cells were seen in early human 
and animal trials.  In addition, no bactericidal or opsonophagocytic antibody 
responses were elicited in the human trial (65).  Safety and Immunogenicity of 
an N-propionylated group B meningococcal polysaccharide conjugate vaccine 
in adult volunteers (In Proceedings of the 10th International Pathogenic 
Neisseria Conference (IPNC), September 8-13, 1996, Baltimore, MD. p.225). 
However, Granoff et al. have shown that certain epitopes of the N-propionyl 
sialic acid polysaccharide generate bactericidal antibodies in mice that do not 
cross react with human polysialic acid residues, thus extending the case for 
further consideration of this vaccine strategy (66).  
1.8.2 Outer membrane vescicle vaccines:  Outer membrane vesicles 
(OMVs) can be generated from meningococcal culture supernatant fluids and 
comprise a lipid bilayer that contains several outer membrane proteins 
(OMPs) and lipooligosaccharides (LOS).  OMVs prepared by detergent 
extraction of whole organisms reduce their LOS content significantly.  Such 
OMV vaccines have been administered with varying results in Chile (67), 
Cuba (16), Brazil (68) and Norway (14).  Recently, one such “tailor made” 
OMV vaccine was successful in containing an epidemic in New Zealand (69). 
However, the main obstacle to the efficacy of these OMV vaccines is the 
generation of a strain-specific antibody response because the majority of 
elicited antibodies are directed against PorA, an outer membrane protein that 
is highly variable across different serogroup B strains. Therefore, an OMV 
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vaccine made from a particular sergroup B strain affords protection only 
against that particular strain but not against diverse strains that cause 
endemic disease and possess heterologous PorA molecules (70).  Another, 
potential problem may be the induction of antigenic shift in PorA or deletion of 
porA genes from infecting strains, which would render the vaccine potentially 
ineffective (71).  An approach under consideration currently is the production 
of OMV vaccines that express several PorA variants that may confer 
protection against a wider array of circulating serogroup B strains (70).   
1.8.3 Protein vaccines:  In 2000, a method called “reverse vaccinology” was 
introduced that was based on genome mining that used computer based 
algorithms to identify genes that encoded the entire genome sequence of N. 
meningitidis (strain MC58) for potential surface exposed protein antigens (72, 
73).  A total of 350 candidate antigens were expressed in Escherichia coli, 
purified, and used to immunize mice.  The sera allowed the identification of 
proteins that were surface exposed, that were conserved in sequence across 
a range of strains and that induced a bactericidal antibody response.  
Experimental evaluation of vaccine potential of most of these antigens 
identified five promising surface antigens: N. meningitidis adhesin A (NadA), 
factor H binding protein (fHbp), Genome-derived Nesseria Antigen (GNA) 
2091, Neisseria heprin binding antigen (NHBA) and GNA1030. Novartis 
Vaccines formulated a vaccine formulation that incorporates these 5 antigens 
into OMVs, called rMenB.  Mice immunized with this formulation generated 
bactericidal antibodies against 78% of a panel of selected serogroup B strains 
(74, 75).  rMenB is currently undergoing clinical trial.  Of note, fHbp was also 
identified as a vaccine candidate by Wyeth (now Pfizer) using an independent 
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approach, which involved fractionation of meningococcal outer membrane 
proteins to identify fractions that yielded bactericidal responses following 
immunization of mice (76).   
Two of the vaccine candidates included in rMenB, called NadA and 
fHbp, have been functionally characterized and may play an important role in 
bacterial pathogenesis. Hypervirulent meningococcal strains that do not 
express NadA are unable to invade human epithelial cells (77). fHbp has been 
shown to bind the alternative complement pathway inhibitor, factor H, which 
enbles meningococci to escape complement-mediated direct killing (78, 79).  
 
1.9 Natural immunity and susceptibility to N. meningitidis 
Most individuals are asymptomatic carriers of N. meningitidis.  Factors 
implicated in the predisposition to meningococcal disease include age 
(highest in infants and adolescents), socio-economic status, climate (more 
commonly seen in winter and in the dry months) and social behavior 
(associated with kissing and cigarette smoking).  Natutral immunity plays a 
key role in protection against meningococcal disease; individuals who lack 
bactericidal antibodies are at risk for invasive disease.   
The importance of complement dependent bacterial killing in protection 
against meningococcal is illustrated by the observation that persons with 
congenital or acquired deficiencies of the complement system and in 
particular, defects of the alternative or terminal pathways are at a significantly 
higher risk for invasive meningococcal disease (discussed below).  
Complement deficiencies are very rare; lack of protective antibodies is more 
common and probably constitutes a more important risk factor.  
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Most individuals clear invading meningococci either by serum-mediated 
bactericidal activity (SBA) or by opsonophagocytosis. The small fraction of 
normal healthy individuals who lack functional antibodies against 
meningococci are more susceptible to infection. Colonization with 
meningococci can be an ‘immunizing’ process.  Bactericidal antibodies that 
are elicited against epitopes shared by heterologous strains may also 
contribute to cross-protection.  Landmark sero-epidemiologic studies 
performed by Goldschneider and colleagues in the 1960s that involved 282 
children (age 0 to 12 years) and military recruits (age 19-26) showed that 
individuals who possessed a serum bactericidal titer (using human 
complement) of 1:4 or greater were likely to be protected against invasive 
disease by serogroups of the test strains (80). I review several hypotheses 
below (1.9.1-4) that might explain acquisition of natural immunity to 
meningococcal disease.  
1.9.1 Exposure to non-Neisserial organisms:  Anti-meningococcal 
antibodies may be elicited following exposure to non-Neisserial 
microorganisms that share surface antigenic features with N. meningitidis. 
The development of IgM antibodies to serogroup B capsular polysaccharide in 
adults (81, 82) may be secondary to repeated exposure to E. coli K1 and 
Moraxella nonliquefaciens.  Both of these organisms can colonize humans 
and have polysaccharide capsules that are chemically identical to group B 
meningococcal capsule (83).  Nevertheless, the significance of cross-reacting 
anti-meningococcal antibodies in protecting against meningococcal disease is 
questionable (84, 85). For example, anti-serogroup B polysaccharide IgG and 
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IgM show low bactericidal activity in the presence of human complement (86, 
87).  
1.9.2 Carriage of non-pathogenic Neisserial species, for example N. 
lactamica: The prevalence of N. lactamica in the nasopharynx is believed to 
be highest during infancy and early childhood (<4 years of age) but decreases 
thereafter.  In contrast, colonization with N. meningitidis is less than 1% 
between infancy to 5 years of age.  It increases thereafter and peaks at 15-19 
years (41, 88-91).  Most of the data on N. lactamica vs N. meningitidis 
carriage in terms of age is derived from a nasopharyngeal swab survey 
conducted in Stonehouse, Gloucestershire in November 1986 (90).  Because 
most cases of meningococcal meningitis occur in children between 6 months 
(when maternal antibodies wane) and 2 years of age (92), and the 
meningococcal carriage rate in this age group is less that 1% (41), the 
immunizing effect of meningococcal colonization is diminished.  However, 
higher rates of colonization with N. lactamica in this age group and resultant 
antibodies elicited against N. lactamica may cross react with N. meningitidis, 
are believed to provide protection against what otherwise could be an even 
higher rate of meningococcal disease in this age group.  Unlike N. 
meningitidis, N. lactamica lacks a capsule; therefore antibodies elicited 
against N. lactamica that cross-react with N. meningitidis target membrane 
proteins and LOS (93-95) 
1.9.3 Asymptomatic carriage of N. meningitdis:  Asymptomatic carriage 
rates of meningococci range from 10-35% in young adults and approach 
100% in closed populations during an epidemic (96, 97).  Hence, 
asymptomatic carriage of N. meningitides is a major contributor to protection 
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against meningococcal disease.  Following carriage, levels of IgG and IgA 
antibodies increase against the colonizing strain, which may provide systemic 
and mucosal protection, respectively (98-103).  Protection induced by 
asymptomatic carriage is usually strain specific as evidenced by a rise in 
antibody titers against noncapsular antigens of the homologous strain. 
Antibodies that develop against capsule during carriage may also 
provide some degree of cross protection against other strains of the same 
serogroup (84, 98, 99, 104, 105).  In addition to protection against the 
homologous strain, a recent study in young adults has shown that colonization 
elicits serum bactericidal antibody activity against heterologous 
meningococcal strains, albeit at lower titers.  Serum bactericidal activity in this 
study was attributed to antibodies directed against outer membrane proteins 
that were conserved across different strains of the same serogroup (106).  
1.9.4. Meningococcal disease: Although meningococcal disease itself may 
protect against future bouts of infection, low incidence rates of meningococcal 
disease (1-3 per 100,000 population in western countries) preclude this mode 
of protection to most people.  An increased level of antibodies directed 
against the infecting meningococcal strain occurs in 45-90% of patients in the 
second week following infection (107-113).  Protective IgG and IgM antibodies 
follow meningococcal disease (84, 109, 112, 114, 115).  These antibodies 
develop against both capsular (81, 111, 116, 117) and noncapsular antigens 
such as outer membrane proteins and LOS (118-123).  In the case of 
serogroup B meningococcal disease most of the resultant protective 
antibodies are directed against subcapsular antigens because the group B 
polysialic acid capsule is poorly immunogenic (124).   
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1.10 The complement system 
The complement system is an important arm of the innate immune 
system against invading pathogens including N. meningitidis.  Almost every 
blood borne bacterial pathogen must have mechanisms to subvert 
complement-dependent killing; four decades ago Roantree and Rantz 
reported that almost every bacterial isolate that caused bloodstream infection 
was resistant to antibody mediated complement-dependent killing (125).  The 
complement cascade consists of three pathways that converge at the level of 
C3 (Figure 1.5).  
1.10.1 Classical Pathway: The classical pathway is most commonly 
activated when an antibody binds to an antigen, as may occur on the surface 
of a microbe. Upon binding to the surface of a pathogen, the Fc portion of the 
antibody undergoes conformational change and binds the C1q(C1r)2(C1s)2 
complex through the C1q subunit.   Antibodies vary in their ability to activate 
complement.  In general, IgM is the most potent activator of the classical 
pathway.  Human IgG3, IgG1 and IgG2 activate complement in decreasing 
order of efficiency; IgG4 does not activate complement.  Binding of the C1q 
subunit induces a change in the confirmation of C1r and subsequently C1s. 
C1s, a serine protease, then cleaves C4 to C4a (released into solution) and 
C4b, which binds covalently to the surface of the pathogen.  C4b possesses a 
highly labile internal thioester residue, which becomes exposed after cleavage 
of C4.  The labile thioester must react with electron-donating –OH groups (or 
–NH2) on surfaces within a very short period (<100 microseconds) or the C4b 
molecule is hydrolyzed and remains in solution. C1s cleaves C2 into C2a and 
C2b.  C2a binds noncovalently to surface bound C4b, to form the C4b,C2a 
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Figure 1.5: Schematic representation of the three pathways of complement.  
Selected (negative) complement regulators are shown in grey shaded areas with 
dashed arrows indicating where they inhibit. 
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complex, the C3 convertase of the classical pathway.  As its name suggests, 
the C3 convertase cleaves C3 to C3b.  Similar to C4, C3 also possesses an 
internal thioester residue.  Cleavage to C3b exposes the thioester and 
progression to binding (or hydrolysis) occurs exactly as it does with C4b 
(described above).  C3b that is bound to surfaces forms a complex with 
C4b,C2a.  The resulting C3bC4bC2a complex functions as a C5 convertase 
that cleaves free C5 to form C5b.  C5b binds to the surface of the pathogen 
and C6, 7, 8 and 9 are successively recruited to form a scaffold that is the 
membrane attack complex (MAC or C5b-9). The MAC forms a hollow tubular 
structure (a pore) that can insert into the membrane of a pathogen and in the 
case of gram-negative bacteria, can initiate lysis and death.  
1.10.2 Mannan binding lectin (MBL) pathway:  The mannan binding lectin 
(MBL) pathway is a more recently described pathway.  MBL is similar in 
structure to C1q and binds to select carbohydrates on pathogenic surfaces, 
which results in the activation of MBL associated serine proteases (MASPs). 
MASP-2 is the best characterized of the MASPs.  MASP-2 cleaves C4 and C2 
to form the C3 convertase that then generates C3b. Subsequent activation 
proceeds as described for the classical pathway.  MASP-1 possesses 
marginal C3 cleavage activity and the function of MASP-3 is not well 
understood.  The MBL pathway also facilitates opsonophagocytosis of 
bacteria by engaging complement receptor (CR) 1 (also called CD35).  MBL 
also binds to meningococcal Opa and PorB through protein-protein 
interactions (126) but the contribution of this interaction to complement 
activation and pathogenesis is not known. 
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1.10.3 Alternative Pathway: The alternative pathway is activated by 
spontaneous hydrolysis of C3 that leads to the generation of C3b. Newly 
generated C3b has a short half-life and must quickly attach to the surface of a 
nearby pathogen or it is hydrolyzed.  Factor B then binds to attached (or 
deposited) C3b to form the C3bB complex; cleavage of B in this complex by 
factor D to Bb results in formation of C3bBb, also known as the C3 convertase 
of the alternative pathway.  C3bBb then cleaves additional C3 molecules to 
C3b, forming a positive feedback loop that perpetuates the process; this is a 
unique feature of the alternative pathway.  Some of the activated C3b 
escapes from the loop and binds to the C3 convertase to form C3bC3bBb, 
also known as C5 convertase, which cleaves C5 to form C5b.  C5b initiates 
the formation of the C5b-9 complex (also called the membrane attack 
complex [MAC]) that leads to lysis and death of gram-negative organisms. 
1.10.4 Regulators of the complement pathway: Activation of the 
complement system can occur spontaneously in the fluid phase and may be 
amplified rapidly, which can be detrimental to host cells.  To limit complement 
activation on foreign surfaces and limit unwanted activation on host cells, the 
complement cascade is tightly regulated by a series of soluble and 
membrane-bound regulators.  Some of the important regulators of the 
complement system are shown in Table I. 
1.10.5 Role of complement pathway in immunity against N. meningitidis: 
Deficiency in terminal complement components C5 through C9 and in 
components of the alternative pathway (properdin, factor D and C3) 
predisposes individuals to meningococcal infections (127, 128).  In fact, the 
only reported disease associated with defects in the terminal pathway and 
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Table 1. Description of Key complement regulators in humans. 
 
 
 
 
    C1 inhibitor 
 
  160  
 
 200 
mg/ml  
 
Binds to C1rC1s and 
dissociates it from C1q. 
Prevents  spontaneous 
activation of C1 in 
circulation. Also inhibits 
MBL-MASP2 activation on 
host cell surface. 
 
Autosomal dominant 
disorder called Hereditary 
Angioedema. Leads to 
uncontrolled activation of C2 
and C4 leading to deficiency 
these complement 
components (256) 
 
 
     Factor I 
 
 
Heavy 
chain: 
35.4 
Light 
chain: 
27.6    
 
 
 35 mg/ml 
 
 
A circulating serine proteae 
that can cleave C3b into 
smaller fragments iC3b and 
then into an even smaller 
C3dg once it binds to host 
cells. Similarly, it cleaves 
C4b to C4c and C4d. 
Factor I requires several 
cofactors for its activity. 
 
 
Autosomal 
recessive.Uncontrolled 
activation of alternate 
pathway results in loss of 
C3 due to consumption. 
Patients are susceptible to 
recurrent infections, 
glomerulonephritis and SLE 
like illness ((126); (257)) 
 
C4 binding 
protein (C4BP) 
 
570 
 
150-300 
mg/ml 
 
Binds to C4b and 
accelerates the decay of 
C4b containing C3 and C5 
convertase by acting as a 
cofactor for factor I ((258); 
(259). In Neisseriae C4BP 
binds to LOS and 
gonococcal Porin. 
 
Only one case reported so 
far. Excess C3 consumption 
and angioedema like 
syndrome (Trapp RG et al, 
1987) 
 
Complement 
Receptor 1(CR1)/ 
CD35 
 
205-
250 
 
Expressed 
on RBCs, 
PMNs, 
DCs. 30-
60 ng/ml 
 
Cofactor for factor I 
mediated cleavage and 
inactivation of C3b and C4b 
(261); (262); (263). It is also 
a receptor for C1q ((264)) 
 
Total CR1 deficiency is 
unknown. 
 
Membrane 
Cofactor of 
Proteolysis 
(MCP/CD46) 
 
51-68 
 
Expressed 
on most 
cells 
except 
RBCs 
 
is an integral membrane 
glycoprotein of most 
mammalian cell 
membranes and is a 
cofactor for factor I 
mediated cleavage of C4b 
and C3b on self tissue 
((265)) 
 
Not known 
 
Decay 
accelerating 
factor 
(DAF/CD55 
 
75 
 
Expressed 
on most 
cells  
 
It competes with factor B for 
binding to C3b and thereby 
prevents the formation of a 
convertase. It can also 
 
Deficiency leads to 
hightened uptake of C3b 
(269) 
Complement 
regulator 
 MW 
(kDa) 
Serum     
level 
        Function             Deficiency 
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dissociate C3b from an 
already formed complex 
with factor B (Nicholson-
Weller A et al, 1982; (266); 
(267); (268) 
 
Properidin 
 
 
 
 
 
 
 
 
 
55 
 
4.3-5.7 
mg/ml 
 
Binds to surface bound C3b 
and stabilizes the C3bBb 
complex and prevents 
cleavage of C3b by factor I 
(270); (271) 
 
X-linked. Defective aternate 
pathway and increased 
susceptibility to 
meningococcal infections 
((272); (273)) 
 
S Protein 
(Vitronectin) 
 
65-75 
 
0.14-0.7 
mg/ml 
Competes with C5b-7 for 
binding to membrane lipids 
and prevents anchoring and 
C9 polymerization ((274)) 
Hereditary disorder is 
autosomal dominant 
Causes thrombosis 
(275)(275). 
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properdin is invasive meningococcal infection.  An effective classical pathway 
is essential for bactericidal activity against Neisseriae (129).  Defects in 
regulation of the alternative pathway results from deficiency of factor H or 
factor I that leads to uninhibited activation of the alternative pathway and 
consumption of C3; these deficiencies predispose individuals to invasive 
meningococcal disease (130, 131).  A single nucleotide polymorphism in the 
promoter region of the factor H (C-496T) gene that results in higher levels of 
circulating factor H has been associated with increased susceptibility to 
invasive meningococcal disease (131); relatively high factor H levels may shift 
the balance of the complement system in favor of inhibition and could interfere 
with effective killing or opsonophagocytosis of meningococci.  Deficiency of 
the MBL pathway also results in predisposition to a variety of pathogens 
including Neisseriae (132).  MBL presumably plays an important role in infants 
who have an immature adaptive immune system and lack sufficient protective 
anti-meningococcal antibodies.  
Persons deficient in terminal complement components C5 through C8 
are ~10,000-fold more susceptible to invasive disease than normal 
individuals; C9-deficient persons are at 10-fold lower risk than persons with 
C5 through C8 deficiencies.  In contrast to sera deficient in C5, C6, C7 or C8 
that does not support bactericidal activity at all, C9 deficient serum supports 
weak antibody-dependent complement-mediated killing, albeit at a rate much 
slower than complement-sufficient serum (133-135). 
Fortunately, inherited complement deficiencies are extremely rare. 
Also, only a small number of patients with meningococcal infections are 
deficient in complement.  Antibody-mediated classical pathway activation 
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remains the most important criterion for protection against meningococci. In 
infants up to the age of 3 to 6 months, protective immunity against invading 
pathogens is mediated by maternal antibodies.  Susceptibility to 
meningococcal infections increases around 6-12 months when maternal 
antibodies wane.  Susceptibility to meningococcal infection decreases with 
progression from early childhood to adulthood possibly because of intermittent 
carriage with N. meningitidis itself or increased colonization with non-
pathogenic strains such as N. lactamica that generates cross-reactive 
antibodies against pathogenic Neisseriae strains (41).  
A detailed understanding of the interaction between the complement 
system and meningococci is required to understand the reasons for increased 
susceptibility to meningococcal infections and to design effective vaccines 
against the pathogen. 
1.10.6 Evasion of complement pathway by Neisseriae: The pathogenic 
Neisseriae, N. meningitidis and N. gonorrhoeae, have evolved several 
mechanisms to evade the detrimental effects of complement to these 
organisms. These pathogens target all arms of the complement cascade 
utilizing several and often redundant mechanisms.  The mechanisms used by 
N. meningitidis to subvert the human complement system are discussed 
below.   
A. Capsular polysaccharide-mediated serum resistance: With rare 
exceptions, all invasive N. meningitidis isolates possesses a polysaccharide 
capsule.  Encapsulated group B and group C meningococci are more 
resistant to killing by normal human serum (serum resistance) than 
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unencapsulated isogenic mutants (136-138).  Earlier work hypothesized that 
that sialic acid residues of the serogroup B capsule recruited factor H, which 
regulated the alternative pathway (136).  However, studies performed with E. 
coli encapsulated with colominic acid (similar in structure to serogroup B 
capsule) (139, 140) and subsequently with serogroup B N. meningitidis 
directly (78, 79) did not invoke a role for factor H binding to capsule. 
Unpublished work in our laboratory indicates that group B and group C 
capsular polysaccharides regulate the alternative pathway by a mechanism 
independent of factor H binding.  The molecular basis of serum resistance 
mediated by the other capsular groups (A, W-135 and Y) remains an area of 
investigation in our laboratory.    
B. Lipooligosaccharide modification and serum resistance:  N. 
gonorrhoeae sialylates LOS (in vitro) by using 5’-cytidinemonophospho-N- 
acetylneuraminic acid (CMP-NANA) as a donor molecule, which leads to 
serum resistance (141-143).  Sialylation of gonococcal LOS enhances factor 
H binding, which results in downregulation of the alternative pathway and 
serum resistance.  Enhanced factor H binding to sialylated gonococci occurs 
through binding to porin rather than to sialylated LOS (144).  LOS sialylation 
enhances factor H binding to meningococci in vitro in select strains only and 
the development of serum resistance is less prominent than with gonococci. 
The role of LOS sialylation in serum resistance is as not well defined in N. 
meningitidis as it is in N. gonorrhoeae. Wild type and sialyltransferase 
deficient (lst) mutants (lacking LOS sialylation) of N. meningitidis are more 
resistant to normal human serum killing but are not different in causing 
disseminated disease in infant rats (137). Nevertheless, most  meningococcal 
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isolates that are invasive in humans express sialylated LOS species, 
suggesting that this LOS structure may confer a survival advantage to this 
bacterium in vivo 
  Upon activation, C4 and C3 bind to their targets through covalent ester 
or amide bonds. In N. gonorrhoeae, C3b and C4b bind to LOS glycose 
residues, gonococcal PorB1.1B, Opa proteins (145) and with certain 
phosphoethanolamine residues on Hep II of LOS (unpublished oservations).  
Edwards and Apicella have shown that C3b also interacts with gonococcal 
lipid A (146).  In N. meningitidis, C4b preferentially forms amide linkages with 
the 6-phosphoethanolamine residue (6-PEA) residues on Hep II of LOS 
preferentially over 3-PEA residues on Hep II (147); reduction in C4b 
deposition on 3-PEA residues may explain why most clinical isolates of N. 
meningitidis express 3-, but not 6-PEA residues on HepII of LOS (148). 
C. Binding to host complement inhibitors: Binding to host complement 
inhibitory molecules such as C4bp and factor H constitutes an important 
mechanism of complement evasion by many microbes.  C4bp binds to 
meningococcal PorA and acts as a cofactor for factor I mediated cleavage 
and inactivation of C4b. PorA positive strains are more serum resistant than 
PorA negative strains (149).  Because the binding of C4bp to meningococci 
and enhanced serum resistance mediated by PorA are most evident under 
hypotonic conditions and in absence of the capsule, the true physiological 
significance of this interaction in vivo remains to be determined.  
Factor H, a key inhibitor of the alternative pathway of complement, 
binds to a 29 kDa meningococcal outer membrane protein designated as 
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factor H binding protein (fHbp) (78, 79), previously called either Genome-
derived Neisserial Antigen (GNA) 1870 (75) or LP2086 (150).  The amount of 
factor H binding is proportional to the level of fHbp expression. Loss of fHbp 
expression increases the sensitivity of meningococci to complement-
dependent killing.  Antibodies against fHbp are bactericidal and fHbp is an 
important component of two group B meningococcal protein vaccines 
undergoing clinical trials (151, 152). 
D. Blocking Antibodies-possible role in Complement pathway 
regulation:  As their name suggests, these antibodies bind to pathogens and 
prevent complement mediated lysis by antibodies that are otherwise 
bactericidal.  Blocking antibodies have also been shown to play a role in 
complement evasion by other pathogens including Brucella abortus (153), B. 
melitensis (154) and Pseudomonas aeruginosa (155, 156) and pathogenic 
Neisserial species e.g. N. gonorrhoeae (157, 158).  Gonococcal strains 
isolated from patients with disseminated gonococcal disease (DGI strains) are 
resistant to killing by normal human serum (serum-resistance) (157). 
Nonbactericidal human serum and more specifically IgG from nonbactericidal 
human serum blocks killing of (human) serum-resistant gonococcal strains by 
bactericidal rabbit sera (162).  Specificity of blocking IgG is directed against 
gonococcal reduction modifiable protein (Rmp) (158).  Human blocking 
antibody (both whole IgG and F(ab)2 fragments) directed against Rmp also 
block killing of gonococci by human killing antibodies that are sometimes 
elicited by patients with DGI (159). While the mechanism of blocking has not 
been fully elucidated, Joiner et al, suggested that blocking antibodies against 
Rmp in N. gonorrhoeae may divert C3 to non-bactericidal targets (159).  
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The role of Rmp (called Class 4 protein in N. meningitidis) as a blocking target 
in N. meningitidis is also not clear (160, 161).  While Munkley et al, have 
shown that a murine monoclonal antibody against Class 4 protein could block 
killing by a bactericidal monoclonal antibody or bactericidal normal human 
serum (160), another group using the same monoclonal antibody observed no 
blocking (161).  
Neisser and Wechsberg gave the first account of blocking activity 
against gram-negative microorganims including Neisseriae in 1901 (196). 
Further evidence of blocking activity directed against N. meningitidis was later 
provided by Lewis Thomas in 1943 (162) who reported that serum obtained 
from rabbits following challenge with high doses of bacteria were less 
bactericidal than preinfection serum.  Furthermore, rabbits re-challenged with 
live N. meningitidis following survival of previous meningococcal infection 
were less likely to survive than normal (control) rabbits.  These findings 
suggested that blocking activity may be an important risk factor in surviving 
meningococcal infection, although the study did not address whether blocking 
activity was a risk factor for acquiring infection and developing disease.  A 
study by Jarvis GA and Griffiss JM, showed that IgA purified from 
convalescent sera from patients with serogroup C meningococcal disease and 
from a recipient of a tetravalent (A, C, W-135 and Y) polysaccharide vaccine 
blocked the bactericidal action of IgG purified from sera of patients 
convalescing from serogroup C meningococcal disease (163).  This IgA1 was 
shown to block the bactericidal activity of serum IgG and IgM against 
serogroup C meningococci distinctly because of relative differences in the 
affinities of IgG and IgM antibodies for their capsular polysaccharide targets 
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(164, 165).  Inhibition of IgG mediated lysis by IgA1 was attributed to 
competition for antibody-binding sites; IgA1 and IgG had similar affinities for 
their targets.  However, IgA1 blocked of lysis by IgM in a non-competive 
manner because of the greater affinity of IgA1 for their targets than IgM. 
Another study done by Selander et al, showed that IgG purified from the 
serum of a healthy sister of a patient (both C2 deficient) suffering from 
recurrent meningococcal infection could block killing of Serogroup W-135 
meningococci by their C2 deficient serum.  The blocking IgG was serogroup 
W-135 specific and reduced C3 deposition on ELISA plates coated with 
serogroup W-135 capsular polysaccharide.  
Both these studies identified blocking anti-meningococcal antibodies in 
convalescent or post-vaccinee human sera (163, 166). So far there is no 
evidence of such complement blocking antibodies in normal human serum. 
Also, the mechanism(s) of blocking has not been fully characterized.  
 
Thesis Objective 
The objective of this thesis is to determine whether blocking antibodies 
can account for differences in killing of serogroup B N. meningitides among 
sera from normal individuals Having defined the antigenic targets for these 
naturally occurring blocking antibodies, I also characterized the molecular 
basis for blocking. 
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Chapter II 
 
Identification of novel blocking human IgG directed against the 
pentapeptide repeat motifs of Neisseria meningitidis Lip/H.8 and 
Laz lipoproteins 
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Abstract 
 
Classical pathway activation initiated by natural antibodies that results 
in bactericidal activity is important for acquired immunity against invasive 
meningococcal disease. Sera from non-immunized individuals vary in their 
bactericidal activity directed against meningococci; in this study, 6/19 sera 
tested lacked bactericidal activity (defined as less than 50% killing of 2.5 X103 
colony forming units [cfus]/ml. of a test strain, in vitro); the remaining 13 sera 
were bactericidal.  Despite possessing high levels of meningococcal-specific 
IgG antibodies, 2 of the 4 sera with the lowest bactericidal activity blocked 
killing of meningococci by 2 of the 4 sera with the highest activity.  Blocking 
was mediated by IgG directed against lipoprotein H.8 that is composed almost 
entirely of pentapeptide AAEAP repeats.  Microbial expression of H.8 and 
another distinct meningococcal lipoprotein, called Laz, which contains 
(imperfect) AAEAP repeats, were both required for maximal display of 
blocking.  The name H.8 was originally assigned to a mAb that identified a 
common surface protein antigen on N. gonorrhoeae; the name H.8 was based 
on the mAb’s location in a 96 well plate (167).   The bactericidal activity of a 
mAb against factor H-binding protein (fHbp; a meningococcal protein vaccine 
candidate), but not an anti-PorA mAb, was reduced by human serum that 
contained anti-H.8 IgG.  Diverting anti-H.8 human IgG away from the bacterial 
surface using synthetic peptides corresponding to H.8, recombinant soluble 
Laz or a non-blocking/non-bactericidal murine mAb against H.8, each restored 
bactericidal activity of the anti-fHbp mAb. Meningococci use blocking 
antibodies present in normal human serum to subvert naturally acquired 
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protective immunity. These findings have important implications for the 
development of meningococcal vaccines, which ideally should overcome 
natural blocking antibody activity and do not themselves stimulate the 
development of blocking antibodies.     
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2.1 Introduction 
N. meningitidis is one of the leading causes of sepsis and bacterial 
meningitis worldwide (15, 168, 169), however, it most often resides as a 
commensal in the human upper respiratory tract and does not elicit  
symptoms.  The incidence of invasive meningococcal disease (about 1 in 
100,000 in non-epidemic settings) is rare relative to the rates of colonization 
(population prevalence of ~10%) (90, 97, 170).  During epidemics and in 
closed populations such as military recruits, the rates of colonization can 
exceed 50% (171).  The rates of invasive disease during epidemics in sub-
Saharan Africa can approach 1% (172). The incidence of meningococcal 
carriage is higher in infants >3 years old and in persons over 30 (173).   
Colonization with meningococci can be an ‘immunizing’ process (100).  
The studies of Goldschneider and colleagues showed that individuals who 
possessed a serum bactericidal titer of 1:4 or greater using human 
complement in the reaction mixtures were likely to be protected against 
invasive disease by the test strain.  Individuals who lacked protective 
antibodies were at higher risk of invasive meningococcal disease (80).  
Bactericidal antibodies elicited against epitopes shared by heterologous 
strains may contribute to cross-protection.   
I sought to determine the reason for the variation among individuals in 
serum bactericidal activity (SBA) against serogroup B meningococci.  Lack of 
antibodies against a test strain would seem the most likely explanation; 
alternatively select bacterial antigens or epitopes may preferentially elicit 
antibody responses that are effete or nonbactericidal.  Another possibility is 
that a subset of nonbactericidal antibodies may interfere with killing by 
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bactericidal antibodies.  Such antibodies are known as ‘blocking’ (or 
subversive) antibodies and have been identified previously in individuals 
recovering from meningococcal disease (163, 165). The identification of 
subversive antibodies that prevent killing by bactericidal antibodies is 
important because it could represent a strategy that meningococci use to 
evade host immune defenses.  Individuals who possess high titers of blocking 
antibodies may be at greater risk for developing invasive meningococcal 
disease.  In addition, blocking antibodies may also undermine the 
effectiveness of meningococcal vaccines.   
 
2.2 Results 
Sera from individuals vary in their ability to mediate complement-
dependent killing against serogroup B N. meningitidis.  
Sera obtained from 19 normal individuals were screened for killing of 
serogroup B N. meningitidis strain H44/76 (Figure 2.1).  The final 
concentration of serum in each bactericidal reaction mixture was 20%.  Sera 
that resulted in ≤50% survival were designated as “killing” (K) sera, while 
those that resulted in >50% survival of bacteria were designated “non-killing” 
(NK) sera.  Heat inactivated ‘K’ sera did not reduce colony counts at t30.  As 
expected, individual sera varied widely in their ability to kill meningococci; < 
50% of bacteria survived (>50% killing) in 13 of the 19 (68%) individual sera 
(labeled as K serum, K1 through K13 in Figure 2.1).  > 50% of bacteria 
survived (< 50% killing) when tested against H44/76 in the remaining 6 sera 
(labeled as NK serum, NK1 through NK6 in Figure 2.1).  
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Figure 2.1. Bactericidal activity of individual human sera against strain 
H44/76. Sera obtained from 19 normal individuals were tested for complement 
dependent bactericidal activity against wild-type N. meningitidis serogroup B 
strain H44/76. The final concentration of each serum in the bactericidal reaction 
mixture was 20%.  Sera that killed ≥ 50% (% survival ≤ 50%) of bacteria were 
designated killing (K) (grey bars) and those that killed <50% (% survival > 50%) 
as non-killing (NK) sera (blank boxes).  All sera displayed normal total hemolytic 
(CH50) activity.
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To examine if lack of anti-meningococcal antibody explained the 
deficiency in bactericidal activity, four of the sera that displayed the highest 
bactericidal activity (K1 through K4) and four sera with the lowest bactericidal 
activity (NK3 through NK6) were selected to examine binding of IgG and IgM 
to strain H44/76 by flow cytometry.  There was no correlation between the 
amount of IgG or IgM that bound to bacteria (Figure 2.2) and the amount of 
killing mediated by the sera (Figure 2.1).  These data suggested that 
differences in bactericidal activity were likely the result of qualitative 
differences in the antibodies present in the killing and non-killing sera.  We 
hypothesized that antibodies present in NK sera were directed against non-
bactericidal targets on meningococci.  In some instances, antibodies directed 
against non-bactericidal epitopes could have possessed blocking activity (i.e., 
antibodies that subvert bactericidal antibody activity (163, 165, 174); I 
addressed this possibility next.   
 
Select non-killing sera block killing by bactericidal sera 
The four sera that possessed the least amount of bactericidal activity 
(NK3, NK4, NK5 and NK6) were screened for their ability to block killing of 
H44/76 by killing sera K1, K2, K3 and K4 (containing the highest bactericidal 
activity).  In this experiment, each of the heat-inactivated (heat treatment 
destroys complement activity but leaves Ab intact) NK sera were incubated 
with H44/76 (20% NK serum in the final reaction mixture) followed by the 
addition (separately) of each of the thawed sera that had originally been 
freshly frozen--killing sera K1 through K4 (10% K serum in the final reaction 
mixture) that contained active complement.  Blocking was defined as ≥ 50% 
40
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reduction in killing of bacteria in the presence of K serum mixed with the heat 
inactivated NK serum compared to killing mediated by the same killing serum 
alone.  Of the 16 reaction mixtures that contained a combination of active K 
and heat-inactivated NK serum, blocking was seen in 3 instances (Figure 2.3 
A; dark grey shaded boxes).  NK3 blocked killing that was mediated by K1 
and K2.  NK4 blocked killing of K1 only.  Four combinations: NK4 plus K2, 
NK5 plus K1, NK5 plus K2 and NK3 plus K3 yielded 25% to 50% blocking 
compared to baseline bactericidal activity in killing serum alone (light grey 
shaded boxes in Figure 2.3 A).  Killing of H44/76 by sera K3 and K4 were not 
blocked by any of the NK sera used. Thus, select NK sera possessed 
blocking activity and conversely, the bactericidal activity of certain K sera 
could be blocked by only select NK sera.   
Killing of wild-type strain H44/76 by K1 (containing endogenous active 
complement) was blocked incrementally (dose responsive) by increasing 
amounts of heat inactivated NK3 added to the reaction mixtures (Fig, 2.3 B). 
In the converse experiment, to examine if antibody in killing serum could 
overcome blocking, heat inactivated K1 (final concentration of 20%) was 
incubated with the organisms, followed by addition of 10% NK3 (complement 
active).  The survival seen with heat inactivated K1 was not statistically 
significant when compared with survival in NK3 alone (Figure 2.3 B).  These 
data provided evidence that a heat-stable component in NK3, likely Ab, could 
prevent killing by K1 and that in the “competition” between killing and blocking 
in human serum, blocking was favored at the antibody concentrations tested.  
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IgG is responsible for blocking  
Prior studies have shown that immunoglobulin (Ig) in serum is 
responsible for blocking killing of Neisseriae (158, 163, 165, 174) The 
experiments above indicated that blocking was mediated by a heat-stable 
molecule in serum.  We hypothesized that Ig in NK3 mediated blocking.  IgG 
and IgM from NK3 were purified and each was tested for its ability to block 
killing of H44/76 by K1.  IgG purified from NK3 (NK3 IgG) blocked killing of 
H44/76 by K1 in a dose-responsive manner (Figure 2.4 A; 2 mg/ml of NK3 
IgG in the reaction mixture corresponds to the amount of IgG contained in 
20% (v/v) serum).  The converse experiment, using IgG depleted NK3 serum, 
showed that depleted serum was no longer effective as a blocking agent 
(Figure 2.4 B).  Only a small increase in survival (~15%) of bacteria was seen 
when 0.2 mg/ml of NK3 IgM (corresponding to the amount of IgM in a reaction 
mixture that contains ~20% (v/v) serum) was added to K1 (10%) serum in the 
bactericidal reaction mixture (Figure 2.4 C; 5th column).  These experiments 
showed that IgG in NK3 was largely responsible for blocking killing by K1.  
 
The bactericidal activity of mAbs directed against selected 
meningococcal vaccine candidates is attenuated by blocking IgG  
Serogroup B meningococcal capsule is not immunogenic; therefore, 
several outer membrane proteins are being investigated for their vaccine 
potential (175).  N. meningitidis outer membrane protein fHbp is one of the 
proteins being investigated as a potential vaccine candidate against group B 
disease (75, 78, 176).  According to one classification scheme, fHbp is divided 
into 3 variant families (75).  Strain H44/76 expresses variant 1 fHbp; an anti-
44
K1
 (1
0%
)
N
K3
 Ig
G
 (m
g/
m
l)
K1
 Ig
G
 (m
g/
m
l)
+
+
+
+
- -
1
2
1-
-
-
**p
>0
.5
% survival
02040608010
0
12
0
A
 
+
K
1 
(1
0%
)
Ig
G
 d
ep
le
te
d 
N
K
3(
%
)
+
+
+
+
N
K
3(
%
)
Heat 
-
-
-
-
-
-
Inactivated
10
20
10
20**
p>
0.
5
02040608010
0
12
0
% survival
B
K
1(
10
%
)
N
K
3 
Ig
M
 (m
g/
m
l)
+
+
+
+
+
-
0.
02
5
0.
05
0.
1
0.
2
% survival
02040608010
0
12
0
C
Fi
gu
re
 2
.4
.  
Ig
G
 in
 N
K
3 
m
ed
ia
te
s 
bl
oc
ki
ng
. A
) I
gG
 p
ur
ifi
ed
 fr
om
 N
K
3 
bl
oc
ks
 k
ill
in
g 
by
 K
1 
se
ru
m
. N
K
3 
Ig
G
 w
as
 a
dd
ed
 
in
cr
em
en
ta
lly
 (f
in
al
 c
on
ce
nt
ra
tio
n,
 1
 a
nd
 2
 m
g/
m
l) 
to
 a
 b
ac
te
ric
id
al
 re
ac
tio
n 
m
ix
tu
re
 c
on
ta
in
in
g 
st
ra
in
 H
44
/7
6 
an
d 
se
ru
m
 
K
1 
(1
0%
 (v
/v
))
. K
1 
Ig
G
 s
er
ve
d 
as
 a
 c
on
tro
l. 
B
) D
ep
le
tio
n 
of
 Ig
G
 fr
om
 N
K
3 
ab
ro
ga
te
s 
bl
oc
ki
ng
 a
ct
iv
ity
. H
ea
t i
na
ct
iv
at
ed
 
Ig
G
-d
ep
le
te
d 
N
K
3 
w
as
 a
dd
ed
 to
 th
e 
ba
ct
er
ic
id
al
 re
ac
tio
n 
m
ix
tu
re
 d
es
cr
ib
ed
 in
 A
.  
Th
e 
co
nt
ro
l u
se
d 
he
at
 in
ac
tiv
at
ed
 N
K
3 
se
ru
m
 in
 th
e 
ba
ct
er
ic
id
al
 re
ac
tio
n 
m
ix
tu
re
. C
) I
gM
 p
ur
ifi
ed
 fr
om
 N
K
3 
do
es
 n
ot
 b
lo
ck
. I
nc
re
m
en
ta
l d
os
es
 o
f N
K
3 
Ig
M
 fa
ile
d 
to
 b
lo
ck
 k
ill
in
g 
by
 K
1.
 In
 a
ll 
ex
pe
rim
en
ts
 (A
, B
 a
nd
 C
) t
he
 y
-a
xi
s 
in
di
ca
te
s 
pe
rc
en
t s
ur
vi
va
l a
nd
 e
ac
h 
co
lu
m
n 
re
pr
es
en
ts
 th
e 
m
ea
n 
(±
S
E
M
) o
f 3
 s
ep
ar
at
e 
ex
pe
rim
en
ts
45
  
variant 1 fHbp mAb called JAR 3 is bactericidal against H44/76 (177).  
Another important component of outer membrane vesicle vaccines is PorA 
that evokes a bactericidal antibody response (106, 178).  mAbs against PorA 
also form the basis for serosubtyping of meningococci; one of these, mAb 
P1.7,  recognizes PorA of strain H44/76 and is also bactericidal (179).   
We examined blocking activity of NK3 IgG upon JAR 3 mediated killing 
of H44/76.  Bacterial survival in the presence of JAR 3 at concentrations of 
0.25 and 0.5 µg/ml was higher in reaction mixtures that contained NK3 IgG 
than in reactions containing IgG-depleted NK3 (Figure 2.5 A).  Increasing the 
concentrations of JAR 3 overcame blocking by NK3 and resulted in 
progressively increased bacterial killing; the presence of NK3 IgG did not 
increase bacterial survival at JAR 3 concentrations of 1.0 and 2.0 µg/ml 
compared to the corresponding reactions that lacked NK3 IgG.  The shift of 
the survival curve to the left when IgG was depleted from NK3 provided 
evidence that IgG in NK3 blocked the bactericidal activity of JAR 3.   
In contrast, depleting IgG from NK3 had no effect on the bactericidal 
activity of anti-PorA mAb P1.7 (Figure 2.5 B).  At any of the dilutions of P1.7 
used, there was no significant difference in the survival rates due to presence 
or absence of the NK3 IgG in the reaction.  These data indicate that blocking 
IgG in NK3 selectively blocks the function of some, but not all, bactericidal 
antibodies. 
 
Identification of lipoprotein H.8 as a target for IgG in blocking serum  
In order to gain a better understanding of why some sera possessed 
blocking activity and why the bactericidal activity of only certain killing sera or 
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Figure 2.5.  Blocking potential depends on the specificity of killing anti-
body.  A) Bactericidal activity of JAR3 (anti-fHbp mAb), but not P1.7 (anti-PorA 
mAb) is attenuated by IgG in NK3.  N. meningitidis strain H44/76 was incubated 
with increasing concentrations (0.25, 0.5, 1, and 2 mg/ml) of JAR 3 in a reaction 
mixture that contained either 20% (v/v) of blocking serum NK3 (Ab and comple-
ment intact; red line and solid circle) or 40% (v/v) IgG-depleted NK3 (blue line 
and solid box).  The higher concentration of IgG-depleted NK3 was used to 
normalize for the amount of hemolytic complement activity in the bactericidal 
reaction mixture (the process of IgG depletion resulted in loss of ~50% of hemo-
lytic activity). B) IgG depletion of NK3 had no effect on the bactericidal action of 
P1.7 (anti-PorA mAb).  Serial dilutions (1/1000, 1/500, 1/250 and 1/125) of ascitic 
fluid containing murine mAb P1.7 were each incubated with strain H44/76 and 
the bactericidal assay performed as described above in A. In all experiments (A 
and B) the y-axis represents percent survival and each data point represents the 
mean (±SEM) of 3 separate experiments. 
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mAbs could be blocked, I examined the specificity of IgG binding to 
meningococcal proteins by western blot using the following representative 
sera; i) blocking serum NK3 ii) non-killing and non-blocking serum NK6, iii) 
killing serum K1 that could be blocked and iv) killing serum K3 that was not 
blocked (Figure 2.6).  To determine the target(s) of blocking IgG, whole 
bacterial lysates of H44/76 were separated on a 4-12% Bis-Tris gel and 
transferred to a PVDF membrane for western blot analysis. 
Whole bacterial lysates of H44/76 probed with NK3 showed a 
prominent IgG-reactive band at ~21 kDa (marked with a black asterisk in the 
2nd of 3 lanes in the NK3 grouping on the left in Figure 2.6) that was not 
visible in the NK6 or K1 groupings and was faint in K3.  This band did not 
correspond to the location of other known outer membrane proteins such as 
Opa, Opc or Class 4 protein; the latter is the homologue of Rmp in N. 
gonorrhoeae, which is the target of blocking antibody in that organism (158). 
An important Neisserial outer membrane antigen that migrates at ~21 kD and 
does not stain with coomassie blue is the lipoprotein H.8 (180-182), also 
called Lip.  
 In preliminary experiments, an anti-H.8 mAb had also shown reactivity 
at the ~21 kD band location (Figure 2.6; lanes marked “H.8/Lip knockout” in 
blots probed with NK3 and K3).  The identity of this band was confirmed as 
Lip/H.8 by loss of reactivity upon deleting lip (Figure 2.6; lanes marked 
“H.8/Lip knockout” in blots probed with NK3 and K3).  The IgG binding pattern 
of blocking serum NK4 was similar to that of blocking serum NK3.  Blots done 
using NK4 also shows a H.8 specific band like NK3 (Figure 2.6; last blot 
labeled NK4).  
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Figure 2.6. H.8 is a meningococcal target for IgG in blocking NK3 serum. 
Bacterial lysates of strain MC58 and its isogenic lipoprotein H.8 knockout (KO) 
mutant were electrophoresed on a 12% Bis-Tris gel followed by western blotting. 
Parallel blots were incubated with a 1:100 dilution of NK3 (extreme left) and NK4 
serum (extreme right), (Both nonbactericidal and possessing blocking activity), 
NK6 (nonbactericidal and without blocking activity), K1 (bactericidal activity that 
could be blocked by NK3) and K3 (bactericidal activity that could not be blocked 
by NK3).  Human IgG-reactive bands were disclosed with alkaline phosphatase 
conjugated anti-human IgG. The black asterisk (on the left) indicates the Lip/H.8-
reactive band (indicated by a solid arrow on the right).  The location of PorA and 
lipooligosaccharide (LOS) reactive bands are shown with arrows on the right. The 
identity of each serum in terms of its bactericidal activity (SBA) and blocking activ-
ity is indicated in the labels below the gel pictures. Sera that lack SBA or blocking 
activity are lablled as n.a. (not applicable) for that particular category.
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Interestingly, the most obvious difference between K1 and NK3 was 
the ~21 kD Lip/H.8-reactive band (depicted by a black asterisk in Figure 2.6 
[1st blot]), which suggested that IgG directed against this antigen may have 
contributed to the blocking activity of NK3.  Serum K3, whose bactericidal 
activity was not blocked by NK3 (Figure 2.3 A), showed a strongly reactive 
band at ~45 kD that likely corresponds to PorA in this strain.  In addition a 
band at ~5 kD (likely lipooligosaccharide; LOS) and other undefined fainter 
bands in the 30-40 kDa range were noted.  The presence of PorA antibodies 
in K3 and the inability of NK3 to block its bactericidal activity are consistent 
with the data in Figure 2.5 B where the bactericidal activity of anti-PorA mAb 
was not affected by the presence of the IgG in NK3.  Subsequent experiments 
were directed at defining the role and specificities of Lip/H.8 and a related 
protein called Laz that shares a region of sequence homology with Lip/H.8 as 
targets for blocking IgG.       
 
Lip/H.8 and Laz are the targets of the human complement blocking 
antibody against N. meningitidis.  
Lip/H.8 is composed entirely of 13-14 tandem repeats of pentameric 
sequences, most (9 to 10) of which are identical “AAEAP” sequences (181). 
The N-terminal ~40 amino acids of another Neisserial lipoprotein called Lipid-
modified azurin (Laz gene of the following neisseriae strains:  Z2491 
(NC_003116.1; gene id 908122), MC58 (NC_003112; Gene id 904058), alpha 
14 (NC_013016.1; gene id 8221802), FAM18 (NC_008767.1; gene id 
4676614), FA 1090 (NC_002946.2; gene id 3281780) among others is 
misannotated and referred to as “H.8” in the sequenced meningococcal and 
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gonococcal genomes) form a domain composed of imperfect AAEAP repeats; 
the remainder of Laz bears similarity to the azurin protein found in organisms 
such as Pseudomonas, Alcaligenes and Bordetella (180, 183).   A sequence 
alignment of these two AAEAP-motif bearing proteins is provided in Figure 
2.7.  
In order to determine the relative contribution of these two lipoproteins 
in blocking, we created Lip/H.8 and Laz knockouts in the background of 
serogroup B strain MC58 (Figure 2.8).  The ability of heat-inactivated NK3 to 
block killing of the mutant strains by K1 was also examined. Loss of either Lip 
or Laz (Figure 2.9 A) restored killing by serum K1 even in the presence of 
heat-inactivated NK3.  Thus, maximal blocking required expression of both 
the lipoproteins. 
I next determined whether loss of Lip/H.8 or Laz expression would 
increase bactericidal activity of anti-fHbp mAb JAR3 in the presence of NK3.  
Akin to observations with strain H44/76 (Figure. 2.5 A), ~95% survival of wild-
type strain MC58 was seen when JAR 3 was added to NK3.  Deleting either 
H.8/Lip or Laz decreased survival by ~25% and ~50%, respectively (Figure, 
2.9 B).  To study the effects of loss of both Lip and Laz on blocking I created a 
‘double’ H.8/Lip and Laz knockout strain but for reasons not fully understood 
this double mutant was highly resistant to complement-dependent killing; no 
killing was seen when this mutant was incubated with 2 µg/ml JAR 3 plus IgG-
depleted NK3 (complement sufficient), or with serum K1, usually our most 
bactericidal serum.  Taken together, these data show that expression of both 
H.8/Lip and Laz were required for maximal blocking by human IgG in NK3. 
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Figure 2.7.  Sequence alignment of N. meningitidis Lip/H.8 and Laz. Alignment of 
amino acid sequences of Lip/H.8 and Laz of serogroup B N. meningitidis MC58.  Lip/H.8 
is a 98 amino acid protein composed almost entirely of the H.8 domain which has 12-15 
conserved AAEAP pentameric repeats depending on the strain (15 in serogroup B N. 
meningitidis MC58). The AAEAP pentameric repeats are emboldened. Each pentameric 
repeat is marked with a bar overhead labeled with the repeat number. Laz is a 183 amino 
acid protein composed of 7 non-conserved, or imperfect, AAEAP pentameric repeats that 
comprises the H.8 domain at its N-terminus (the 7 imperfect repeats of Laz correspond in 
position to the first 7 conserved pentameric repeats of Lip/H8).  The C-terminal portion of 
Laz (amino acid residues 57 to 183) is homologous to bacterial copper binding proteins 
called azurin. Both proteins are lipid modified at the cystine residue (marked by an itali-
cized C at position18) following cleavage of the N-terminal 17 amino acid signal 
sequence. Conserved amino acids between the H.8 domain of both proteins are shown.
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Figure 2.8. Western Blot analysis of strain wild type MC58 and its Lip/H.8 and Laz 
knock out isogenic mutants. Bacterial lysates of strain MC58 and its isogenic Lip/H.8 
and Laz single knockout mutants (L to R) were electrophoresed on a 12% Bis-Tris gel 
followed by blotting and incubation with 2C3 (anti-H.8 mAb). The western blot was 
disclosed using alkaline phosphatase conjugated goat anti-mouse IgG. Bands specific 
for Lip/H.8 and Laz are indicated.
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Figure 2.9. Expression of both Lip/H.8 and Laz are required for maximal blocking.  
A) Wild type strain MC58 (black bars) and its isogenic Lip/H.8 (green bars) and Laz 
deficient  (red bars) mutants were incubated with 10% (v/v) killing serum K1 and 20% 
(v/v) heat inactivated blocking serum NK3. Percent survival is shown on the y-axis.  Mean 
(±SEM) of 3 separate experiments is shown. B) Loss of Lip/H.8 or Laz expression 
increases killing by JAR 3 (anti-fHbp mAb) in the presence of NK3. Wild-type MC58 and 
its Lip/H.8 and Laz mutants were incubated with JAR 3 (0.25 µg/ml) and NK3 (20% (v/v)).  
In all experiments (A and B) percent survival is indicated on the y-axis and each column 
represents mean (±SEM) of 3 separate experiments. 
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Murine anti-H.8 mAb, 2C3 inhibits the blocking activity in human serum 
mAb 2C3 binds to both Lip/H.8 and Laz (184). Unlike human IgG 
directed against H.8, the anti-H.8 mAb, 2C3, does not possess blocking 
activity (Figure 2.10 A).  
 I tested mAb 2C3 for its ability to inhibit binding of human blocking IgG 
that would result in restoration of killing (Figure 2.10 B).  The ability of 2C3 to 
restore killing would provide evidence that the target for human blocking IgG 
against N. meningitidis is H.8. Strain H44/76 was incubated with 20% NK3, 
0.25 µg/ml JAR 3 and increasing doses (2.5, 5 and 10 µg/ml) of mAb 2C3.  
The mAb 2C3 antibody restored killing by JAR3 in a dose-responsive manner 
similar to that produced by 0.25 µg/ml of JAR 3 plus antibody free human 
complement (~20% survival; see Figure 2.5 B).  This restoration of killing is 
not due to a synergistic effect of 2C3 on the bactericidal activity of JAR3. 
F(ab)2 fragments of mAb 2C3 restore killing by JAR3 in NK3 serum similar to 
whole 2C3 IgG (Figure 2.10 C).  In addition to providing further proof that 
Lip/H.8 and Laz are targets for blocking IgG human serum, these data 
suggest that blocking function is unique to human IgG, but not murine mAb 
2C3, despite recognition of both antibodies to similar or overlapping epitopes.  
 
Killing of meningococci is restored by diverting blocking Ab from the 
bacterial surface with Lip/H.8 or Laz peptide fragments  
I tested the ability of synthetic peptides that corresponded to the N- and C- 
termini of Lip/H.8 and contain perfect AAEAPs to inhibit or divert the binding 
(and therefore the function) of human blocking IgG.  I used increasing 
concentrations of the two 30-mer synthetic peptides either individually or in an 
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equimolar mixture. I added these to bactericidal reaction mixtures that 
contained NK3 (20%) and JAR 3 (0.25 µg/ml).  Bacterial killing increased with 
the addition of increasing concentrations of the two peptides to the reaction 
both individually as well as in an equimolar mix  (Figure 2.11 A).  The peptide 
corresponding to the C-terminus of Lip/H.8 had a slightly greater effect on 
restoration of killing compared to the peptide corresponding to the N-terminus. 
Control reactions included JAR 3 plus IgG-depleted NK3 with or without the 
Lip/H.8 peptides.    
I also tested the ability of recombinant Laz (rLaz; not lipidated, but 
containing the N-terminal imperfect AAEAP repeats) to inhibit blocking using 
the assay described above.  Soluble rLaz also restored killing by JAR 3 in a 
dose-dependent manner (Figure 2.11 B).  A His-tagged recombinant protein 
that contained only the Azurin-like domain and lacked the N-terminal AAEAP 
repeat did not restore killing by JAR 3 (Figure 2.11 C), thereby confirming 
blocking specificity to the N-terminal AAEAP domain of the protein Laz.  
Controls included the addition of recombinant proteins to reaction mixtures 
that contained JAR3 as the killing antibody and complement (IgG-depleted 
NK3); these had no effect on killing of the bacteria (Figure 2.11 A, B, C).  
Collectively, these data provide strong evidence that the H.8 pentapeptide 
motifs of Lip/H.8 and Laz contribute to bacterial survival by serving as targets 
for blocking antibodies in human serum.  
 
2.3 Discussion 
Serum bactericidal activity (SBA) is widely accepted as a surrogate of 
natural or vaccine induced protective immunity against N. meningitidis (80, 
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84).  SBA titers against meningococci vary substantially among individuals. 
Most persons have been exposed to N. meningitidis and they usually mount 
an antibody response against the colonizing strain.  The specificity of the 
antibody response elicited by colonization may be heterogeneous (106); the 
protective potential against a given strain depends on epitope specificity, and 
subclass distribution and titer, which are factors that combine to determine 
whether fixation of complement on the bacterial surface results in SBA.  So far 
in this thesis, I have shown that antibodies in the sera from about 10% of 
individuals that I tested prevented serum bactericidal antibody function.  Using 
several approaches, I have provided evidence that these antibodies are 
directed against the repeating pentapeptide ‘AAEAP’ sequences of H.8/Lip 
and the N-terminus of lipid modified azurin (Laz), which possesses ‘imperfect’ 
repeats; these antibodies block killing by select bactericidal antibodies.  
H.8 was discovered when a series of monoclonal antibodies (mAbs) 
generated by immunizing Balb/c mice with outer membrane preparations of 
gonococcal strain FA1090 identified, by western blot, H.8 in all 48 gonococcal 
and 25 meningococcal strains (the latter represented serogroups A, B, C, X 
and Y).   mAb to H.8 also bound to 4 of 5 N. lactamica strains but not to other 
commensal strains tested (N. subflava, N. perflava, N. mucosa, N. flava, N. 
flavascens).  Further analysis of FA1090 outer membrane preparations using 
SDS PAGE and western blotting revealed that H.8 migrated at ~20 kDa in 
samples prepared at 37oC; bands sizes of 30 kDa were also seen when 
samples were prepared at 100oC.  The H.8 antigen has unique properties.  
Because of its composition that lacks aromatic amino acids (181, 182, 185); 
H.8 cannot be stained by Coomassie blue or by silver and does not yield an 
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absorbance at 280 nm.  Following the discovery of H.8 (167), the 
characterization of H.8 antigen was motivated by interest in identifying a 
surface exposed outer membrane protein antigen common to all disease 
causing Neisseriae spp. for potential use as a universal vaccine candidate 
(119, 181, 182, 185, 186).  Antibody responses to H.8 were observed in 
subjects with disseminated gonococcal and meningococcal infections (119). 
However, a subsequent study refuted the possibility of H.8 mediating 
protection against Neisseriae (187).   
Only pathogenic Neisseriae possess H.8/Lip (167); except for the 
commensal sp. N. lactamica which on occasion has been reported to cause 
disease (188, 189).  H.8 has been found in all strains of pathogenic 
Neisseriae that have been examined for H.8/Lip (the lip gene has been 
misannotated in published meningococcal genomes), suggesting an important 
role for this molecule in pathogenesis.  My data suggest that expression of 
this protein serves to elicit a separate antibody response that attenuates 
bactericidal antibody activity thereby providing a survival advantage to 
meningococci.  
 Azurin is involved in defense against oxidative stress and copper 
toxicity; Neisseria mutants that lack lipid modified azurin (Laz) are highly 
sensitive to hydrogen peroxide and copper (190).  Azurin is also expressed by 
other bacteria such as Pseudomonas aeruginosa (183).   However, the 
presence of the N-terminal “H.8-like” motif appears to be a feature unique to 
pathogenic Neisseriae.  The peptapeptide repeats in Laz also contribute to 
blocking antibody targets; “replication” of an H.8-like motif in Laz could also 
serve to maximize the efficiency of blocking against Laz.  Indeed, both Lip/H.8 
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and Laz expression are necessary to provide the maximal number of target 
sites for blocking antibody.  It may be noteworthy that a double mutant in 
MC58 that lacked both lip/H.8 and Laz was more resistant to complement 
dependent killing.  However, this may occur at the expense of the important 
functions of Laz as described above and might place the bacteria at a 
disadvantage in vivo.  
Blocking antibodies in normal human serum prevented killing by an 
anti-fHbp mAb, but did not prevent killing by an anti-PorA mAb.  As an 
example of supremacy of killing over blocking in a purely human system, 
serum specimen K3, contained both IgG anti-PorA and anti-H8 (Figure 2.6) 
and maintained killing even when additional H.8-specific human antibody 
(heat-inactivated NK3) was added (Figure 2.3 A).  Although antibodies against 
other meningococcal antigens may also be bactericidal, nevertheless PorA is 
one of the most abundant protein targets for antibody in the meningococcal 
outer membrane. Antibodies directed against PorA are often present in 
normal sera that contain SBA (106) and this antigen elicits a significant 
proportion of SBA in humans vaccinated with outer membrane protein 
vaccines (191).  Factor H binding protein (fHbp) is a relatively sparsely 
distributed 29 KDa outer membrane lipoprotein that is currently being 
investigated as a candidate for a group B meningococcal vaccine (75, 150). 
As its name suggests, this lipoprotein binds factor H, a major inhibitor of the 
alternative pathway of complement (78).  Our findings may have important 
implications for vaccine development because bactericidal activity of 
antibodies directed against less abundant antigens may be blunted in persons 
with higher titers of anti-H.8 antibodies.  Based on our experiments using 
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mAbs and human blocking IgG, killing was restored by increasing the 
concentration of anti-fHbp mAb in reaction mixtures.  
           Blocking antibodies directed against the pathogenic Neisseria vary in 
their target specificity. Antibodies against gonococcal reduction modifiable 
protein (Rmp) mediate blocking against N. gonorrhoeae.  Rmp is an outer 
membrane structural protein of approximately 30 kDa whose function has not 
been fully elucidated (192).  A monoclonal antibody against the class 4 protein 
of N. meningitidis  (the Rmp counterpart in N. meningitidis) blocked the killing 
of meningococci by otherwise bactericidal antibody or serum in one study 
(160) but the same antibody showed little or no blocking activity against N. 
meningitidis in a separate study (161).  Likewise, human anti-H.8 antibodies 
that block killing of N. meningitidis do not block killing of N. gonorrhoeae (my 
unpublished observations conducted with colleagues in the Rice/Ram 
laboratories).  Anti-Rmp blocking antibodies activate complement and deposit 
C3 and C9 on the surface of N. gonorrhoeae (159).  While not formally proven 
to occur as a result of blocking antibodies per se, serum-resistance of N. 
gonorrhoeae is associated with larger polymers or aggregates of C5b-9 (193) 
or as C5b-9 complexed to distinct bacterial outer membrane constituents 
(194).  Qualitative differences in bactericidal versus nonbactericdial C5b-9 in 
N. gonorrhoeae was suggested by two-fold greater release of 125I-C9 from 
C5b-9 inserted into serum-resistant strains (193).  It has been hypothesized 
that anti-Rmp blocking antibodies divert C3 deposition from bactericidal sites 
on the bacteria to non-bactericidal sites (159). The effects of anti-H.8 
antibodies on complement activation on meningococci and the molecular 
basis of blocking mediated by human anti-H.8 antibodies merit further study.  
62
  
            The phenomenon of blocking of bacterial killing was described as 
early as 1894 by Pfeiffer who noted that animals given excess immune serum 
may be more susceptible to challenge organisms (195).  The first written 
account of blocking serum activity was provided by Neisser and Wechsberg, 
who showed blocking of normal fresh animal serum mediated killing of a 
range of gram negative micro-organisms by immune sera obtained from 
animals that were immunized with whole bacteria (196).  Lewis Thomas et al. 
observed that antisera from rabbits immunized with larger doses of 
meningococci were less bactericidal than animals immunized with a lower 
dose. The bactericidal activity was restored upon diluting the antiserum 
obtained from the heavily immunized rabbits.  When these sera were heat 
inactivated and mixed with normal rabbit serum, killing of meningococci was 
abolished. Furthermore, rabbits that were passively immunized with the 
heavily immunized antiserum showed impaired clearance of meningococci. 
This inhibitory effect of heavily immunized rabbit sera is specific for 
meningococci and is abrogated upon absorption of the serum against the 
immunized meningococcal strain (162).  In a preceding publication, Lewis 
Thomas et al. also showed that sera from patients convalescing from 
meningococcal disease were sometimes less bactericidal than acute (non-
immune) serum.  This inhibitory effect of heavily immunized rabbit sera is 
specific observation made only in case of patients of meningococcal 
meningitis (197).  This may have been the first recorded evidence of blocking 
antibodies against meningococci (162, 197).  
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Blocking IgA1 has also been identified in sera of patients following group C 
meningococcal disease and post-serogroup C capsular vaccinees (163, 165). 
Jarvis and Griffiss have shown that serum IgA derived from either 
convalescent sera from disseminated group C meningococcal meningitis 
cases or adult volunteers given tetravalent (A, C, W135, Y) vaccine could 
block IgG mediated lysis of serogroup C N. meningitidis (163).  The blocking 
IgA1 was directed against the serogroup C capsular polysaccharide and did 
not inhibit binding of IgG to the bacteria and is therefore directed against a 
distinct capsular epitope(s).  A novel type of blocking IgG against serogroup 
W-135 N. meningitidis was also demonstrated in the serum of a healthy C2-
deficient sister of a forteen year old girl diagnosed with serogroup W-135 
meningitis.  Following vaccination of both the patient and her healthy sibling 
with tetravalent polysaccharide meningococcal vaccine, the healthy sister 
developed blocking IgG directed against group W-135 capsule (166).  
Blocking antibody that reduces bacterial killing has also been shown following 
Brucella abortus (153), B. melitensis (198) and Pseudomonas aeruginosa 
(155, 156) infections. Anti-LPS antibodies have been shown to block 
complement mediated killing of non-typhoid salmonella in convalescent sera 
of HIV-positive patients in Africa (199).  Our data are the first to identify 
blocking anti-meningococcal antibodies in otherwise healthy persons who 
have not had preceding meningococcal disease or meningococcal 
vaccination.   
            Effective capsular polysaccharide-based vaccines are licensed against 
serogroup A, C, W-135 and Y N. meningitidis.  However, there is no effective 
vaccine available against group B N. meningitidis.  Several protein antigens, 
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including fHbp, have been identified as potential vaccine candidates against 
serogroup B N. meningitidis (74, 75, 78, 150, 175, 176, 179, 191).  While I 
have shown that the bactericidal efficacy of an anti-fHbp mAb is 
disproportionately reduced in the presence of anti-H.8 human antibodies, 
compared do anti-Por mAb, the effect of these blocking antibodies on 
polyclonal anti-fHbp antibodies elicited by immunization of humans is not 
known.  Outer membrane vesicles (OMVs) often used as vaccines (14, 104, 
123, 200, 201) or as carriers for protein vaccine antigens contain Lip/H.8 
and/or Laz and may therefore elicit blocking antibodies and attenuate 
bactericidal responses.  
In conclusion, I have identified naturally occurring human blocking 
antibodies that are directed against the H.8-pentapeptide repeat motifs of the 
Lip and Laz lipoproteins of N. meningitidis.  These results suggest an 
important role for these peptide repeats in meningococcal pathogenesis and 
may explain why these repeats occur in two distinct proteins that are 
ubiquitously expressed in pathogenic Neisseriae.  Antibody-mediated 
complement-dependent killing is critical for host defense against Neisseriae.  I 
have characterized an important strategy employed by this bacterium to 
subvert a key immune defense that may have important implications for 
vaccine development. 
 
2.4 Materials and Methods 
Bacterial strains 
N. meningitidis strains H44/76 (B:15:P1.7,16: ST-32; invasive isolate 
from Norway (1976)) (202) and the serologically closely related strain MC58 
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(B:15:P1.7,16: ST-74; invasive isolate (United Kingdom (1985)) (6) have been 
described previously.   
 
Human serum 
Sera obtained from 19 healthy adult human volunteers without prior 
history of meningococcal disease were aliquoted and stored at –80o C until 
used.  Sera were used only once within 1 hour after thawing.  Total hemolytic 
complement (CH50) of sera was measured using the Total Haemolytic 
Complement kit (The Binding Site) or the EZ Complement CH50 assay 
(Diamedix Corporation) according to the manufacturers instructions.  For 
some experiments, sera were heated to 56o C for 30 min to destroy 
complement activity.  
 
Ethics statement 
This study was approved by the Committee for the Protection of 
Human Subjects in Research at the University of Massachusetts Medical 
School.  All subjects who donated blood for this study provided written 
informed consent. 
  
Monoclonal antibodies 
  mAb JAR 3 (IgG3) that recognizes variant 1 meningococcal factor H-
binding protein (fHbp) that is expressed by strains H44/76 and MC58) was 
provided by Dr. Dan M. Granoff (Children’s Hospital Oakland Research 
Institute) (203).  Anti-PorA mAb P1.7 (ascites fluid) was purchased from the 
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National Institute of Biological Standards and Control (Potters Bar, 
Hertfordshire, U.K).   
 
Serum bactericidal assays 
Bacteria taken from an overnight culture on chocolate agar plates were 
re-passaged onto fresh chocolate agar and allowed to grow for 6 h at 37°C in 
an atmosphere containing 5% CO2. Approximately, 2000 CFU of 
meningococci were incubated with serum (concentrations specified for each 
experiment), purified proteins, peptides or antibodies; the final reaction 
volume was maintained at 150 µl.  Aliquots of 25 µl of the reaction mixtures 
were plated onto chocolate agar in duplicate at the beginning of the assay (t0) 
and again after incubation at 37°C for 30 min (t30).  Survival was calculated as 
the number of viable colonies at t30 relative to t0.  Heat inactivated killing sera 
were tested separately for loss of killing activity when complement was 
destroyed (complement control). 
 
Preparation of IgG depleted serum  
All manipulations were performed at 4 °C.  To deplete IgG, 2 ml of 
serum containing 10 mM EDTA to minimize complement activation, was 
passed over a 1 ml protein G sepharose column (Sigma Catalog No. P3296; 
binding capacity >20 mg human IgG/ml) equilibriated with Tris-buffered saline 
(TBS); pH 7.  The fall through material (absorbed serum) was spin- 
concentrated and dialyzed against TBS using a 10kDa cut off Amicon Ultra-15 
centrifugal filter device (Millipore).  The absorbed serum was concentrated to 
near its original volume and stored as single-use aliquots at -80º C.  Depletion 
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of IgG was confirmed by flow cytometry, where complete loss of IgG binding 
to H44/76 was observed (Figure 2.12).  The hemolytic activity of IgG depleted 
serum was quantified following reconstitution with 2 mM Ca++ and 2 mM Mg 
(resultant C50H ~50%).  I used a two-fold higher concentration of depleted 
serum vs. the intact serum counterpart in functional bactericidal assays to 
account for loss of hemolytic activity during manipulation of serum.  
 
IgG and IgM purification 
IgG that had bound to protein G sepharose following passage of serum 
through the column (as described above) was eluted with 0.1 M glycine-HCl, 
pH 3.0, and neutralized immediately with 0.2 M Tris in 0.5 M NaCl, pH 8.0. 
Protein containing fractions were spin-concentrated and dialyzed against 
TBS, pH.7 (TBs) using an Amicon-15 Ultra device (30 kDa cutoff).   
IgM was purified by passage of serum over an anti-human IgM agarose 
column (Sigma), followed by elution and neutralization as described above.  
Spin-concentration and dialysis against TBS was performed using an Amicon-
15 Ultra device (100 kDa cutoff).  IgG and IgM concentrations were estimated 
by the Bradford assay.  
 
Flow cytometry analysis 
Binding of human IgG and IgM to N. meningitidis was determined by 
flow cytometry as described previously (147).  Briefly, 10 µl of serum was 
added to 108 bacteria suspended in 90 µl Hank’s Balanced Salt Solution 
(HBSS) for 30 min at 37 °C.  Bacteria were washed and bacteria-bound IgG 
and IgM were detected using FITC conjugated anti-human IgG and anti-
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Figure 2.12. IgG depletion from NK3 serum.  N. meningitidis serogroup B strain H44/76 
was incubated with non-killing NK3 serum (solid black plot) or IgG-depleted NK3 (Dashed 
plot). IgG binding to bacteria determined by flow cytometry using anti-human IgG-FITC. 
The secondary antibody control (solid grey plot) represents bacterial incubation in the 
absence of serum. 
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human IgM (both from Sigma).  Data were generated using a BD 
FACSCalibur (Becton Dickinson) flow-cytometer and analyzed using FlowJo 
software (Tree Star, Inc.).  
 
Western blotting 
Western blotting was used to determine binding of human IgG to 
meningococcal antigens.  Bacterial lysates were separated on a 4–12% Bis-
Tris gel (Invitrogen Life Technologies) using 2-(N-morpholino) ethanesulfonic 
acid (MES) running buffer, pH 7. Proteins were transferred to PVDF 
membranes (Millipore) and blocked with PBS-1% dry milk for 30 min at 24° C. 
Membranes were then incubated with heat-inactivated NHS (diluted 1:100 in 
PBS-0.05% Tween 20) for 15 h at 4°C.  Membrane-bound IgG was detected 
using alkaline phosphatase conjugated anti-human IgG (Sigma) at a dilution 
of 1:1000 dilution in PBS-0.05% Tween 20 and 5-bromo-4-chloro-3-indolyl 
phosphate/nitro blue tetrazolium (BCIP/NPT) purple liquid substrate (Sigma; 
Cat No. B3679).  
 
Lip/H.8 deletion (lip) mutants and insertional inactivation of laz 
Chromosomal DNA isolated from an H.8 knockout mutant of N. 
gonorrhoeae strain F62 (204) was used to transform N. meningitidis strain 
MC58 and transformants were selected on GC agar plates containing 
chloramphenicol (5 µg/ml) and loss of Lip/H.8 expression was confirmed by 
western blotting (Figure 2.9).  
To construct the laz deletion mutant of strain MC58, chromosomal DNA 
isolated from a Laz knock out gonococcal strain F62. In order to make the F62 
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Laz::erm mutant, bps 40-184 of the laz open reading frame (ORF), which 
includes the signal sequence, was replaced with an erythromycin resistance 
(erm) marker using overlap extension PCR described herein.  DNA extracted 
from strain F62 was used as a template, and a 329 bp fragment upstream of 
bp 40 and a 359 bp fragment downstream of bp 184 of the laz ORF were 
amplified using primer pairs 5′ CGGCAGGGATGTTGTAAATATC 3′ (LAZ-UP-
FOR) and 5′-GTTCCTATTTTTTGGATAACGGCGGCAGAAATCAGA-3′ (LAZ-
UP-REV)and 5′-TGA ACAAGATGAGTCTGACGAATCCAACGACAATATGC-
3′ (LAZ-DOWN-FOR) and 5′-GTTCATCAAAGCACCGTGACCC-3′, (LAZ-
DOWN-REV) respectively (the emboldened underlined sequences overlap 
with the erm marker).  The erythromycin resistance marker was amplified 
using genomic sequence of mutant gonococcal strain F62::lgtE::erm 
(unpublished) as a template with primers 5’ GCCGCCGTT ATCCAAAAA 
ATAGGAACACGAAAAACAAG 3’ (ERM-FOR) and 5' GTTGGA TTCGTCAG 
ACTCATCTTGTTCATATTTATCAG 3' (ERM-REV) (the emboldened 
underlined sequences overlap with laz).  The three PCR products were gel 
purified and linked by overlap extension using primers LAZ-UP-FOR and LAZ-
DOWN-REV.  The resulting 1527 bp product was cloned into TOPO 2.1, 
linearized with ScaI and used to transform strain F62.  Erm resistant colonies 
were selected on GC agar containing Erm (2.5 µg/ml).  Interruption of laz was 
verified by PCR and loss of Laz expression by western blotting The strain 
MC58 was transformed with this DNA and the transformants were selected in 
GC agar plates containing erythromycin (5mg/ml) (Figure 2.9). 
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Generation of IgG F(ab)2 fragments. 
Anti-H.8 mAb 2C3 was digested using immobilized pepsin bound to 
agarose beads in Tris-Cl buffer, pH 6 for 4hrs at 37oC while shaking. The 
beads were spun down at 2000rpm for 5min. The F(ab)2 fragments in the 
supe was purified using sepharose G beads and spin-concentrated and 
dialyzed against Tris Buffered saline, pH. 7, using Amicon-15 Ultra device (30 
kDa cutoff).  Generation of F(ab)2 was checked by running untreated and 
pepsin treated mAb 2C3 on a 4-12% Bis-Tris Gel followed by staining with 
coomassie stain.  
 
Synthetic Lip/H.8 peptide fragments 
The synthetic Lip/H.8 fragments Lip N30 (representing the N-terminal 
30 amino acids of the Lip/H.8 from residues 18 to 47 with the Met residue in 
the signal peptide was designated as amino acid no. 1; peptide sequence 
CGGEKAAEA PAAEAPAAEAPATEAPAAEAP]) and Lip C30 (representing 
the C-terminal 30 amino acids of Lip/H.8 spanning residues 68 through 97 
plus an added N-terminal Cys residue [peptide sequence 
CAEAAATEAPAAEAAATEAPAAEAPAAEAAK] were synthesized by Genway 
Biotech and used to inhibit binding of putative blocking IgG .  
 
Cloning and expression of recombinant Laz-6xHis and Azurin-6xHis 
proteins 
laz was amplified from MC58 chromosomal DNA using primer pair 
rLAZ-FOR (5′ GGAATTCCATATGTCTCAAGAACCTGCCGCGCC 3′; the 
NdeI site is emboldened and underlined) and rLAZ-REV (5′ CCG CTCGAGA 
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TCGACCAAAGTCACTTTGCCG 3′; the XhoI site is emboldened and 
underlined).   The 496 bp amplicon encoded laz without the N-terminal Cys 
residue and also lacked the stop codon. The resulting PCR product was 
cloned into the NdeI-XhoI sites of pET-21a (EMD Biosciences, cat. no. 69740-
3) that introduces a C-terminal 6xHis tag.  The plasmid, called pET-21a-Laz-
His, was transformed into E. coli strain BL-21 (DE3) pLysS.  Laz expression 
was induced with 0.3 mM IPTG and the recombinant protein was purified from 
inclusion bodies following lysis of bacteria with B-PER lysis buffer (Pierce # 
78243) supplemented with lysozyme (200 mg/ml) followed by nickel-affinity 
chromatography.  The recombinant protein was analyzed for purity by 
coomasie staining and the presence of the His-tag was confirmed using 
western blot analysis with an anti-poly histidine mAb (Sigma; cat # H1029).  
The presence of the “H.8-like” domain of Laz (the N-terminal 35 amino acids 
that are organized into imperfect ‘AAEAP’ pentapeptide repeats) was revealed 
by western blotting with anti-H.8 mAb 2C3 (205).  
Similarly, the azurin domain of Laz (lacks the“H.8-like” N-terminal 35 
amino acid domain that contains imperfect AAEAP repeats) was also 
expressed as a recombinant protein in E. coli.  The azurin domain of laz was 
amplified from the MC58 chromosomal DNA using primers: Azurin-FOR (5′ G 
GAATTCCATATGGGCAACTGTGCGGCAACTGTC 3′; the NdeI site is 
emboldened and underlined) and Azurin-REV (5′ CCGCTCGAGATCGACCAA 
AGTCACTT TGCCG 3′; the XhoI site is emboldened and underlined).  
Cloning into pET21a and purification of His-tagged recombinant azurin was 
performed as described for Laz.   
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Statistical Analysis 
Percent of survival of bacteria with 95% confidence interval around the 
mean percentage is shown in the figures.  Differences in percentage survival 
were assessed for significance using a two tailed paired student t test (p<than 
0.05 are indicated as * and < 0.005 are indicated as **). 
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Chapter III 
Mechanism of action of anti-H.8 Blocking IgG 
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Abstract 
Serum mediated bactericidal activity (SBA) is an important arm of 
natural immunity against N. meningitidis.  Complement deficiency, lack of 
specific bactericidal antibodies against meningococci and complement 
blocking antibodies constitute several factors that affect SBA.  Although 
blocking antibodies have been identified against meningococci previously, 
their mechanism of action has not been well defined.  Anti-Rmp antibodies 
against N. gonorrhoeae are believed to divert C3 to “ineffective” targets on the 
meningococcal surface (159), while anti-capsular blocking IgA1 against group 
C meningococci probably sterically hinder binding of otherwise bactericidal 
IgG or IgM.  Anti-H.8 blocking IgG from select nonbactericidal sera blocked 
killing of meningococci by otherwise bactericidal mAbs against a 
meningococcal vaccine candidate called factor H-binding protein (fHbp).  IgG 
from blocking serum that contained anti-H.8 did not hinder binding of anti-
fHbp mAbs.  Blocking anti-H.8 IgG downregulated classical pathway 
activation (C4 deposition) by anti-fHbp mAb.  Blocking activity required N-
linked oligosaccharides of the Fc region.  Furthermore, blocking IgG also 
required participation of a heat stable serum factor for its activity.  Our 
preliminary data indicates that this serum factor may be mannan binding lectin 
(MBL).  These findings provide important insights into the mechanism of 
action of blocking IgG against N. meningitidis, emphasizing differences 
between blocking IgGs directed against different members of the Neisseriae 
family.  This work also highlights a role for specific IgG glycosylation patterns 
in modulating complement activation on meningococci. 
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3.1 Introduction 
In Chapter II, I have identified novel SBA blocking IgG in normal human 
serum directed against ‘AAEAP’ motifs in the H.8 outer membrane protein of 
serogroup B N.meningitids.  In this chapter I propose to understand and 
partially characterize the mechanism of blocking activity. 
Serum immunoglobulins (Ig) are critical components of the humoral 
immune system (206).  IgG is the most abundant Ig molecule in human 
serum.  Typically, an IgG molecule is composed of two heavy and two light 
chains linked to each other by disulfide bonds.  Each heavy chain consists of 
three constant regions or domains (CH1, CH2 and CH3) and a variable 
domain (VH). Each light chain consists of a constant region/domain (CL) and 
a variable domain (VL).  The constant and variable domains of the two light 
chains (CL and VL) together with the constant and variable domains of the 
two heavy chains (CH1 and VH) comprise the two Fab fragments.  The 
constant regions/domains of the two heavy chains (CH2 and CH3) comprise 
the Fc fragment. (Figure 3.1 A) (206-208).  The Fab portion dictates specificity 
of binding to antigens while the Fc portion is involved in numerous biological 
effector functions.  Upon binding its cognate antigen, the antibody undergoes 
a conformational change that triggers Fc-mediated effector functions that aid 
in clearing invading pathogens.  Two important Fc functions include: 1) Fcγ 
receptor mediated uptake of antibody-opsonized pathogens by immune cells 
such as neutrophils and macrophages; 2) activation of the classical 
complement pathway that leads to C3b (and then iC3b) deposition that 
promotes opsonophagocytosis through the CR1 and CR3 receptors and 3) in 
the case of gram-negative organisms, further activation of the complement 
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cascade that leads to insertion of the membrane attack complex (C5b-9) and 
results in lysis and killing of orgnisms (208).  Antibody mediated activation of 
the classical complement pathway (CP) is an important arm of the immune 
system that facilitates clearance of meningococci (127, 128).  
Immunoglobulins (Igs) are glycoproteins and Ig glycosylation is 
essential for their biological effector functions.  The Asn297 residue of the CH2 
domain of Fc region of IgG in serum is a site for substitution with a N-glycosyl 
residue (208, 209).  This N-linked oligosaccharide substitution is critical for 
both Fcγ receptor and complement activation (208, 210).  Typically, the 
oligosaccharide chain is made up of a core biantennary structure (Figure 3.1 
A); heterogeneity of the glycans results from differences in the composition of 
the terminal sugar residues (Figure 3.1 B) (207, 208, 211).  Glycan 
heterogeneity plays a critical role in modulating IgG effector functions (212).  
In this chapter, I show that the N-linked oligosaccharide substitution of 
the Fc region is essential for the blocking activity of anti-meningococcal H.8 
blocking IgGs present in normal human serum.  I also show that blocking IgG 
requires Fc N-glycosylation to down-regulate classical complement pathway 
activation by antibodies that are otherwise bactericidal.  Furthermore I show 
that downregulation of C4 deposition by blocking IgG may possibly require 
mannan binding lectin (MBL), a heat-stable serum factor.  Contrary to its 
‘conventional’ role as a complement activator, here I speculate a possible 
inhibitory role for MBL in complement activation on N. meningitidis.  Futher 
experiments are required to validate this observation. 
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3.2 Results 
Blocking by IgG requires the Fc domain.  
            To examine which parts of blocking antibody molecules are required 
for blocking, I first generated F(ab)2 fragments from blocking IgG present in 
serum NK3 (Figure 3.2 A).  I tested F(ab)2 fragments for their ability to inhibit 
bactericidal activity of anti-fHbp mAb JAR 3 (intact blocking IgG served as a 
positive control) using IgG-depleted NK3 as the source of complement.  
Unlike gonococcal blocking, where F(ab)2 derived from blocking IgG is 
stoichiometrically simlar in blocking potency (158, 159).  I observed that loss 
of the Fc portion of the NK3 IgG abrogated its ability to block killing by JAR 3 
(Figure 3.2 B).   
 
The N-linked oligosaccharides of the blocking serum IgG Fc region are 
required for blocking activity.  
Immunoglubulin isotype (or subclass) plays an important role in 
dictating which of the four IgG subclasses will activate complement. The 
hierarchy of complement activation by human IgG subclass is: IgG3 > IgG1 > 
1gG2 >> IgG4 (213).  Western blotting experiments revealed that blocking 
antibody in NK3 that was specific for H.8 was IgG3 (antibody disclosure used 
subclass specific conjugated anti-serum (Figure 3.3).  Therefore, non-
activation of complement by blocking IgG antibody (as might be expected with 
IgG4) was an unlikely explanation of the blocking phenomenon.  
Having demonstrated that the Fc domain of IgG was required for 
blocking, I speculated that a glycan residue on Fc may play a role in blocking.  
The structure of Fc glycans modulates the effector functions of IgG (206-208). 
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Figure 3.2. Blocking anti-H.8 IgG requires Fc for blocking. A) Pepsin and untreated NK3 
IgG were electrophoresed on a 12% Bis-Tris gel followed by either coomassie staining (right 
panel) or western blotting with anti-human IgG (left panel) to confirm the separation of 
F(ab)2 (~110 kDa) from the rest of the IgG (~160 kDa) molecule. B) F(ab)2 recovered from 
digested  NK3 IgG was added in increasing concentrations (white bars; final concentrations 
0.5 and 0.1 mg/ml) to a bactericidal reaction mixture containing strain H44/76, mAb JAR3 
and IgG depleted serum NK3, 20% (v/v) used as the complement source The corresponding 
doses of whole NK3 IgG (grey bars) served as a control. Each bar shows the mean percent 
survival (±range) of 2 separate experiments.
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The IgG purified from blocking serum NK3 was deglycosylated using the 
endoglycosidase Peptide N-Glycanase, PNGase (Figure 3.4 A). 
Deglycosylation did not affect binding of NK3 IgG to H44/76 (Figure 3.4 B).  A 
bactericidal assay was performed where untreated blocking IgG and 
deglycosylated blocking IgG were compared for their abilities to block the 
bactericidal effect of anti-fHbp mAb, JAR 3; IgG-depleted serum NK3 was 
used as the complement source.  I observed that the deglycosylated  NK3 IgG 
failed to block killing by JAR 3 (Figure 3.4 C).  
  
Blocking serum IgG mediates blocking by reducing classical pathway 
activation by anti-fHbp monoclonal antibody. 
Early events following binding of a complement-fixing (or bactericidal) 
Ab to a bacterial surface includes engagement of the C1 complex, activation 
of C4 and deposition of C4b on the bacterial surface.  Surface-bound C4b 
then participates in the formation of classical pathway C3 and C5 
convertases, which results in membrane attack complex insertion and 
bacterial lysis and killing.   I asked whether human blocking IgG interfered 
with classical pathway activation by bactericidal antibody.  In these 
experiments, strain H44/76 was incubated with the complement source (IgG-
depleted NK3) and bactericidal mAb JAR 3, either alone or in the presence of 
intact purified NK3 IgG or PNGase-treated IgG.  C4b deposition on bacteria 
was measured by flow cytometry.  The presence of blocking IgG significantly 
decreased JAR 3-mediated deposition of C4b on wild-type serogroup B stain 
H44/76.  C4b deposition was mostly restored when deglycosylated NK3 IgG 
was substituted, as depicted by mean fluoroscent intensity and histogram 
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Figure 3.4. Blocking IgG requires Fc N-linked oligosaccharides to maintain blocking 
function. A) Deglycosylation of NK3 IgG by PNGase. Untreated and PNGase treated NK3 
IgG were electrophoresed on a 12% Bis-Tris gel followed by either coomassie staining to 
monitor IgG deglycosylation. The deglycosylated NK3 IgG (3rd lane from left; PNGase +ve) 
migrates faster than the untreated IgG (2nd lane from left; PNGase –ve). B) Similar binding of 
untreated and PNGase-treated NK3 IgG to N. meningitidis. Serogroup B N. meningitidis strain 
H44/76 was incubated with 100 µg untreated (black plot) or deglycosylated (PNGase treated) 
NK3 IgG (dashed plot). IgG binding to bacteria was determined by flow cytometry using anti-
human IgG-FITC. The secondary antibody control (grey shaded areea) represents bacterial 
incubation in the absence of blocking IgG. C) Loss of Fc glycan is associated with loss of 
blocking activity.  Increasing (0.5 and 1 mg/ml) concentrations of deglycosylated (PNGase-
treated) NK3 IgG (white bars) was added to a bactericidal reaction mixture containing strain 
H44/76, mAb JAR3 and IgG depleted serum NK3 (20% (v/v)) used as the complement source. 
The corresponding concentrations of untreated NK3 IgG (grey bars) served as a control. The 
y-axis indicates percent survival and each column represents the mean (±SEM) of 3 separate 
experiments.
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plots (Figure 3.5 A, B).  Controls included reaction mixtures that contained the 
complement source alone, complement plus intact blocking IgG and 
complement plus PNGase-treated blocking IgG; no increase in C4b 
deposition above levels seen with C’ alone was seen in any of the other two 
controls, thereby showing that neither the intact or PNGase-treated blocking 
IgG activated the classical pathway by itself (Figure. 3.5 A).  The level of 
classical pathway activation was independent of the amount of NK3 IgG or 
anti-fHbp mAb binding to the bacteria (Figure 3.5 D, E).  
 
Blocking serum IgG does not effect classical pathway activation by anti-
PorA monoclonal antibody.   
In chapter II, I showed that blocking IgG did not block the bactericidal 
activity of a mAb against an abundant meningococcal outer membrane 
protein, PorA.  In accordance with those observations, I show here that NK3 
IgG did not diminish classical pathway activation by anti-PorA mAb, P1.7 
(Figure 3.6 A, B). Binding of NK3 blocking IgG (Figure 3.6 C) and Por1.7 (anti-
PorA mAb; Figure 3.6 D) were both ensured in these experiments.   
 
Terminal sialylation of the N-linked Glycans of the blocking IgG is not 
responsible for its blocking activity. 
Terminal α(2,6)-linked sialic acid residues of Fc N-linked 
oligosaccharides on IgG molecules downregulate inflammation by activating 
inhibitory Fcγ RIII receptors on immune cells (214).  The level of sialyation of 
serum IgG is highly variable (215) and the role of terminal α(2,6)-linked sialic 
acid in complement activation is not completely understood.  I hypothesized 
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Figure 3.5. Blocking IgG inhibits the classical pathway activation of complement by 
JAR 3 mAb (anti-fHBP). N. meningitidis serogroup B strain H44/76 was incubated with 
mAb JAR3, IgG depleted NK3 serum used as a source of complement (C’) and 100 µg of 
either untreated or PNGase-treated NK3 IgG. C4b deposition on bacteria was determined 
by flow cytometry and used as a measure of classical pathway activation.  A) C4b deposi-
tion on bacteria (average of the geometric mean fluorescence of 2 experiments) mediated 
by JAR3 and IgG depleted serum NK3 (complement [C’]) in the presence of NK3 IgG or 
PNGase-treated NK3 IgG.  B) Histograms from one representative experiment in A. show-
ing C4b deposition on bacteria X-axis; fluorescence on a log10 scale; y-axis, counts. C) 
Levels of NK3 IgG binding in NK3 containing reactions and D) levels of JAR 3 binding in 
JAR 3 containing reactions. All FACS plots representing bacteria incubated are color coded 
as follows:  C’ (solid grey plot); C’+JAR3 (Green plot); C’+JAR3+NK3 IgG (red plot) and 
C’+JAR3+ PNGase+ve NK3 IgG (blue plot).
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Figure 3.6. Blocking serum IgG does not inhibit classical pathway activation by 
Por1.7 mAb (anti-Por A). N. meningitidis serogroup B strain H44/76 was incubated with 
mAb Por1.7, IgG depleted NK3 serum used as a source of complement (C’) and 100 µg of 
NK3 IgG. C4b deposition on bacteria was determined by flow cytometry and used as a 
measue of classical pathway activation.  A) C4b deposition on bacteria (average of the 
geometric mean fluorescence of 2 experiments) mediated by P1.7 and IgG depleted serum 
NK3 (complement [C’]) in presence or absence of NK3 IgG. B) Histograms from one repre-
sentative experiment in A shoing C4b deposition on bacteria. X-axis; fluorescence on a 
log10 scale; y-axis, counts. C) levels of NK3 IgG binding in NK3 containing reactions and D) 
levels of Por1.7 binding in Por1.7 containing reactions. All FACS plots representing bacteria 
incubated are color coded as follows: C’ (solid grey plot); C’+NK3 IgG (blue plot); C’+Por1.7 
(green plot) and C’+Por1.7+ NK3 IgG (red plot).
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that negatively charged terminal sialylation of blocking IgG N-linked glycans 
could be responsible for blocking activity, perhaps by interfering with C1q 
binding to proximate bactericidal antibodies. C1q-Fc interactions are ionic in 
nature and are influenced by charge (216).  Alternately, terminally sialylated 
blocking IgG could recruit complement inhibitors such as C4bp and/or factor H 
that have the capacity to bind to polyanions and thereby inhibit complement 
activation.  In order to determine the role of terminal sialic acid residues of N-
linked oligosaccharides of blocking IgG upon its function, I successfully de-
sialylated whole IgG purified from blocking serum using α(2,6) specific 
neuraminidase (Figure 3.7 A) and tested two doses of either untreated 
blocking IgG or desialylated blocking IgG for their ability to block the 
bactericidal activity of anti-fHBP mAb JAR (Figure 3.7 B).  Loss of sialylation 
of blocking IgG did not inhibit its blocking activity.  Interestingly, and contrary 
to my expectations at the time, I observed enhancement of blocking by 
desialylated blocking IgG compared to untreated IgG.  This unpregulation of 
the blocking effect upon desialylation could be due to unmasking of particular 
sugar residues of the Fc N-linked glycans that possibly mediate or may be 
required for blocking. 
 
‘Blocking’ serum IgG requires a heat stable serum factor to block  
Several steps precede the deposition of C4b on a surface and 
interference with any of these steps could account for reduced C4b deposition 
that was seen in the presence of effective blocking by ‘blocking’ IgG.  
Engagement of the C1 complex by Fc, activation of C4 by C1s in the C1 
complex and availability of targets for the activated metastable C4b molecule 
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Figure 3.7. Desialylation of blocking serum IgG increases blocking activity. A) Confir-
mation of desialylation of IgG.  Neuraminidase treated and untreated NK3 IgG were electro-
phoresed on a 12% Bis-Tris gel followed by western blotting and probing with anti-human 
IgG alkaline phosphate which served as a ‘loading control’ (left panel) or with biotinylated 
Sambrucus Niagra Lectin and alkaline phosphatase conjugated streptavidin to monitor 
desialylation (right panel). B) Either untreated (grey bars) or Neuraminidase treated (white 
bars) NK3 IgG was added incrementally (final concentration, 0.5 and 1 mg/ml) to a bacteri-
cidal reaction mixture containing strain H44/76, mAb JAR3 and IgG depleted serum NK3 
(20%) used as a complement source. Corresponding doses of untreated NK3 IgG served 
as a control.  The y-axis indicates percent survival and each column represents the mean 
values (±SEM) of 3 separate experiments.
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must occur prior to C4b deposition on bacteria.  As a first step in addressing 
this question, I attempted to ‘recreate’ the phenomenon of decreased C4b 
deposition by blocking IgG using purified complement components C1 and 
C4.  C4b deposition was measured when strain H44/76 was incubated with 
purified C1 and C4 and JAR 3 either alone or in the presence of intact NK3 
(blocking) IgG or PNGase-treated NK3 IgG (blocking ability lost).  Reaction 
mixture containing only purified C1 and C4 without any antibody served as 
control for background (spontaneous) C4 activation and deposition.  Reaction 
mixture containing sheep anti-C4b mAb and FITC conjugated goat-anti sheep 
IgG served as probing antibody control.  Surprisingly, I observed that blocking 
IgG failed to affect a decrease in classical pathway activation by the JAR3 
when purified C1 and C4 were used (Figure 3.8 A).  However, downregulation 
of the classical pathway by the blocking IgG was restored upon addition of 
heat inactivated complement (IgG depleted blocking serum NK3) to the 
reaction mixture that contained C1 and C4 (Figure 3.8 B).  The level of 
downregulation of classical pathway in this case was comparable to that 
caused by NK3 IgG on JAR3-mediated classical pathway activation when ‘IgG 
depleted NK3 serum’ was used as a complement source (Figure 3.8 C).  The 
heat inactivated ‘IgG depleted blocking serum NK3’ showed minimal classical 
pathway activation by JAR3 (Figure 3.8 D).  Thus, the blocking IgG requires 
an additional heat stable serum factor(s) in order to mediate its blocking 
activity against bactericidal mAb JAR3.  
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Figure 3.8. Blocking activity of NK3 IgG requires participation of a heat stable 
serum factor. N. meningitidis serogroup B strain H44/76 was incubated with mAb JAR3 
alone (green plot) or along with NK3 IgG (1 mg/ml, red plot) or PNGase-treated NK3 IgG 
(1 mg/ml, blue plot) in presence of one of the following used as a complement (C’) source 
indicated above each FACs plot: A) purified C1 (pC1) and C4 (pC4), B) pC1 and pC4 
mixed with heat inactivated (IgG depleted NK3 serum, C’) IgG, C) IgG depleted NK3 
serum, C’ and D) heat inactivated IgG depleted NK3 serum. Baseline level of C4 activa-
tion by C’ alone (in the absence of any antibody) is shown by a dashed black line. Back-
ground binding of the detector antibody (anti-C4 IgG + FITC-sec Ab) binding is shown by 
solid grey shading. Classical pathway activation in presence of each complement source 
is depicted as level of C4b binding. X-axis; fluorescence on a log10 scale; y-axis, counts.
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Mannan binding lectin (MBL) may be a possible heat stable factor 
required by the blocking IgG to block the bactericidal activity of JAR3.  
MBL is a collectin family member found in the serum of most mammals 
that specifically binds to glucans, lipophosphoglycans and glycoinositol 
phospholipids that contain mannose, glucose, fucose or N-acetylglucosamine 
(GlcNAc) as their terminal hexose (217-219) (113).  MBL is associated with 
three MBL associated serine proteases (MASPs), MASP-1 (220, 221), MASP-
2 (222) and MASP-3 (223).  Of these MASP-1 activates C3 directly (222, 224, 
225) and MASP-2 cleaves C4 (226). MBL and C1q have been shown to 
compete for binding to human endothelial cells (227).  IgG N-linked glycans 
terminating in N-acetyl glucosmanine or mannose bind MBL (228) and show 
reduced classical pathway activation due to lack of binding to C1q (229).  I 
hypothesized that MBL could be the heat stable serum factor that acted 
together with blocking IgG to block the bactericidal activity of antibodies such 
as JAR3. MBL deficiency is relatively common, although complete lack of 
MBL in serum is rare (132).  I utilized serum from an MBL-deficient individual 
described in an earlier publication from our laboratory (230) (Figure 3.9 A).  
IgG and IgM were depleted from this MBL-deficient serum to remove 
background antibody-dependent bactericidal activity for use as a complement 
source.  I compared the ability of NK3 IgG to block the bactericidal activity of 
JAR3 in presence of one of two complement sources: i) either IgG and IgM 
depleted MBL-deficient serum or ii) IgG depleted NK3 serum (MBL-sufficient) 
(Figure 3.9 B).  I showed that while the NK3 IgG blocks the bactericidal 
activity of JAR3 in presence of MBL-sufficient complement source, it was an 
ineffective blocker in MBL-deficient complement (Figure 3.9 B).  These results 
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indicate that MBL could possibly be the heat stable serum factor required for 
the activity of blocking activity of IgG in NK3.  However, further experiments 
are required to confirm and validate this finding. 
 
3.3 Discussion 
N. meningitidis is a major cause of bacterial meningitis epidemics 
worldwide.  Only a small percentage of the general population is susceptible 
to meningococcal infections although a relatively large percentage is 
asymptomatic nasopharyngeal carriers.  A major reason for variation in 
susceptibility to menigococcal infection is the difference in serum bactericidal 
activity against meningococci among individuals. In chapter II, I have shown 
that diminished SBA in some individuals occurs because of the presence of 
complement blocking IgG antibodies directed against pentameric ‘AAEAP’ 
motif contained in meningococcal outer membrane proteins Lip and Laz.  In 
this chapter I showed that blocking IgG against N. meningitidis inhibits the 
SBA by downregulating the classical pathway of complement.  Blocking 
requires glycosylation of the Fc portion of blocking IgG (Figure 3.4).  This is in 
contrast with the mechanism of blocking against N. gonorrhoeae which does 
not require Fc (159).  My results highlight important differences in the 
mechanism of blocking IgG in human serum directed against N. meningitidis 
and N. gonorhoeae.   
In human IgG, Asn 297 in the CH2 domain of the constant region is 
substituted with N-linked oligosaccharides (Figure 3.1 A) (208, 209).  Fc 
linked oligosaccharide is necessary for a number of antibody effector 
functions, including complement activation and antibody directed cell 
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cytotoxicity (208)208, (231, 232).  Heterogeneity of the N-linked 
oligosaccharides can be manifest by differing terminal sugars including sialic 
acid, galactose or N-acetyl gluosamine; these sugar substitutions influence 
antibody effector functions (212). A possible role for MBL in blocking is 
consistent with the requirement of Fc glycan in mediating blocking.  I have not 
yet characterized the terminal sugars present in Fcs of blocking antibody but 
identification of sugar-specific terminal substitutions on Asn 297-linked 
oligosccharides of blocking antibodies may strengthen the hypothesis of MBL 
being a part of the blocking antibody mechanism.  I speculate that the Fc 
glycan of blocking IgG possesses either a terminal GlcNAc or mannose 
residue, which may enable it to engage MBL.  Efforts to characterize the 
terminal glycan residue of the IgG are currently underway.  Kaneko et al. have 
shown that terminal sialylation of IgG glycans inhibits inflammatory response 
mediated by human intravenous immunoglobulin (IVIG) preparations (214).  
However, I showed that sialylation has no role in facilitating blocking (Figure 
3.7).  On the contrary, desialylation of the blocking IgG enhanced its blocking 
activity.  The inverse correlation between IgG sialylation and blocking also 
indirectly suggests the involvement of serum factor/s e.g. MBL in blocking 
because ‘capping’ of glycans by sialic acid decreases binding of MBL and 
possibly other serum factors (233).  
 It seems unlikely that MBL, which is an activator of the complement 
system, would directly contribute to blocking.  I speculate that MBL may serve 
to recruit molecules that inhibit complement.  Two candidates include α2-
macroglobulin and C1 inhibitor.  Previous work in our laboraory showed that 
MBL in the context of serum did not activate complement on N. gonorrhoeae 
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because of the inhibitory effects of α2-macroglobulin and C1 inhibitor on MBL 
(230).  However, the exact mechanism used by these two molecules to render 
MBL ineffective in enhancing complement activation on gonococci was not 
defined. Several studies have shown that MBL is associated with α2-
macroglobulin (234-236) in serum, making my speculation plausible.   
            MBL deficiency predisposes to a variety of pathogenic infections (132) 
and its role in immune defenses may be particularly important in individuals 
who lack a mature repertoire of antibodies, particularly infants older that 3-6 
months and young children.  In these situations, MBL may serve as a 
substitute antibody functioning as an opsonin. MBL deficiency has been cited 
as a risk factor for meningococcal disease, but how MBL protects against this 
infection is not well understood (90).  The level of binding of MBL to both N. 
meningitidis and N. gonorrhoeae (237, 238) is inversely proportional to the 
level of sialylation of lipooligosaccharide (LOS). MBL has been shown to 
initiate lysis and death of N. gonorhoeae only when pre-incubated before 
addition of potentially bactericidal serum (230).    
       I am currently purifying anti-H.8 specific antibody from serum by affinity 
chromatography over immobilized H.8/Lip. Once obtained, the N-linked 
glycans of the anti-H.8 blocking IgG will analyzed by mass spectroscopy. 
Although quite preliminary and speculative, this study privides a lead towards 
a possible negative role of MBL in complement activation and imparts an 
important role for Fc glycans in regulating complement activation on 
Neisseria.  These findings have important implications for antibody-mediated 
immunity against pathogens. 
 
96
  
3.4 Materials and Methods 
Bacterial strains 
N. meningitidis strains H44/76 (B:15:P1.7,16: ST-32; invasive isolate 
from Norway (1976)) (202) and MC58 (B:15:P1.7,16: ST-74; invasive isolate 
(United Kingdom (1985)) (6) have been described previously. Gonococcal 
strain 1291A has been used to analyze MBL binding (230) . 
 
Monoclonal antibodies 
   mAb JAR 3 (IgG3) that recognizes variant 1 meningococcal factor H-
binding protein (fHbp) that is expressed by strains H44/76 and MC58) was 
provided by Dr. Dan M. Granoff (Children’s Hospital Oakland Research 
Institute).  Anti-PorA mAb P1.7 (ascites fluid) was purchased from the 
National Institute of Biological Standards and Control (Potters Bar, 
Hertfordshire, U.K). 
 
Serum bactericidal assays 
Bacteria taken from an overnight culture on chocolate agar plates were 
re-passaged onto fresh chocolate agar and allowed to grow for 6 h at 37°C in 
an atmosphere containing 5% CO2.  Approximately, 2000 CFU of 
meningococci were incubated with IgG depleted serum (concentrations 
specified for each experiment), antibodies; the final reaction volume was 
maintained at 150 µl.  Aliquots of 25 µl of the reaction mixtures were plated 
onto chocolate agar in duplicate at the beginning of the assay (t0) and again 
after incubation at 37°C for 30 min (t30).  Survival was calculated as the 
number of viable colonies at t30 relative to t0.  The ability of purified NK3 IgG to 
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reduce the killing activity of a bactericidal reaction mixture by ≥50% compared 
to the baseline level of killing was defined as ‘blocking’.   
 
Preparation of IgG depleted serum  
All manipulations were performed at 4 °C.  To deplete IgG, 2 ml of 
serum containing 10 mM EDTA to eliminate complement activation, was 
passed over a 1 ml protein G sepharose column (Sigma Catalog No. P3296; 
binding capacity >20 mg human IgG/ml) equilibriated with Tris-buffered saline 
(TBS); pH 7.  The fall through material (absorbed serum) was spin- 
concentrated and dialyzed against TBS using an Amicon Ultra-15 centrifugal 
filter device (Millipore).  The absorbed serum was concentrated to near its 
original volume and stored as single-use aliquots at -80º C.  Depletion of IgG 
was confirmed by flow cytometry, where complete loss of IgG binding to 
H44/76 was observed (Figure 2.12).  The hemolytic activity of IgG depleted 
serum was quantified following reconstitution with 2 mM Ca++ and 2 mM Mg 
(resultant C50H ~50%).  * We used 2X concentration of depleted serum vs. the 
intact serum counterpart in functional bactericidal assays to directly compare 
depleted with intact sera, 
 
IgG purification 
IgG that had bound to protein G sepharose following passage of serum 
through the column (as described above) was eluted with 0.1 M glycine-HCl, 
pH 3.0, and neutralized immediately with 0.2 M Tris in 0.5 M NaCl, pH 8.0. 
Protein containing fractions were spin-concentrated and dialyzed against Tris 
Buffered saline, pH. 7, using Amicon-15 Ultra device (30 kDa cutoff).  
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Generation of Blocking serum IgG F(ab)2 fragments. 
Purified NK3 IgG was digested using immobilized pepsin bound to 
agarose beads (Pierce# 9001-75-6) in Tris-Cl buffer, pH 6 for 4hrs at 37oC 
while shaking. The beads were spun down at 2000rpm for 5min. The F(ab)2 
fragments in the supe was purified using sepharose G beads and spin-
concentrated and dialyzed against Tris Buffered saline, pH. 7, using Amicon-
15 Ultra device (30 kDa cutoff).    
 
IgG De-glycosylation 
Purified NK3 IgG was deglycosylated by incubation with 500U of 
PNGAse (NEB# P0705S) in sodium phosphate buffer, pH. 7.5, overnight at 
37oC. Deglycosylation of IgG was detected by running on 4-12% bis-Tris gel 
followed by staining with Imperial blue stain to see a distinct shift in migration 
of 150kDa IgG band. Deglycosylated IgG was then purified using a sepharose 
bound protein G beads and spin-concentrated/dialyzed against Tris Buffered 
saline, pH. 7 using an Amicon-15 Ultra device (30 kDa cutoff). 
 
IgG De-sialylation. 
Purified NK3 IgG was desialylation by incubation with 100 U of a 2-6/a 
2-3 neuraminidase (NEB#P0720S) in sodium phosphate buffer, pH. 7.5 
overnight at 37oC. Desialylated IgG was then purified using a sepharose 
bound protein G beads and spin-concentrated/dialyzed against Tris Buffered 
saline, pH. 7 using an Amicon-15 Ultra device (30 kDa cutoff). 
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Flow cytometry analysis 
Binding of human IgG and classical complement pathway components 
to N. meningitidis was determined by flow cytometry as described previously 
(147).  Briefly, 40 µl of IgG depleted blocking serum along with anti-fHBP mAb 
was added to 108 bacteria suspended in 90 µl Hank’s Balanced Salt Solution 
(HBSS) in presence or absence of purified blocking IgG for 30 min at 37 °C. 
Bacteria were washed and bacteria-bound IgG and classical complement 
pathway components were detected using FITC conjugated anti-human IgG 
(from Sigma) and anti-human C1q, C3 and C4 (from molecular probes). 
Binding of MBL in serum to N. meningitidis was incubating the bacteria 
incubating with the specific serum followed by primary probing with anti-MBL 
mAb 3E7 and secondary probing with FITC conjugated goat anti-mouse IgG. 
Data were generated using BD FACSCalibur (Becton Dickinson) flow-
cytometer and analyzed using FlowJo software (Tree Star, Inc.). 
 
Western blotting 
Western blotting was used to determine binding of human IgG to 
meningococcal antigens.  Bacterial lysates were separated on a 4–12% Bis-
Tris gel (Invitrogen Life Technologies) using 2-(N-morpholino) ethanesulfonic 
acid (MES) running buffer, pH~7.  Proteins were transferred to PVDF 
membranes (Millipore) and blocked with PBS-1% dry milk for 30 min at 24° C. 
Membranes were then incubated with heat-inactivated NHS (diluted 1:100 in 
PBS-0.05% Tween 20) for 15 h at 4°C.  Membrane-bound IgG was detected 
using alkaline phosphatase conjugated anti-human IgG (Sigma) at a dilution 
of 1:1000 dilution in PBS-0.05% Tween 20 and 5-bromo-4-chloro-3-indolyl 
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phosphate/nitro blue tetrazolium (BCIP/NPT) purple liquid substrate (Sigma; 
Cat No. B3679).  To determine level of sialylation of IgG binding to 
meningococcal antigens, blots were blocked with PBS-1% BSA for 30 min at 
24° C.  Sialylation of membrane-bound IgG was detected using biotinylated 
Sambrucus niagra Lectin and alkaline phosphatase conjugated streptavidin 
(Sigma) at a dilution of 1:1000 dilution in PBS-0.05% Tween 20 and 5-bromo-
4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NPT) purple liquid 
substrate.  
Generation of F(ab)2 fragments of purified IgG was detected by running 
untreated and immobilized pepsin treated IgG on 4-12% bis-Tris gel followed 
by staining with either 1) Imperial blue stain to see distinct 150kDa and 
100kDa bands for whole IgG and F(ab)2 fragments or 2) transfer to a PVDF 
membrane followed by probing with alkaline phosphatase conjugated goat 
anti-human IgG Fab specific antibody.  Deglycosylation of IgG was detected 
by running on 4-12% bis-Tris gel followed by staining with Imperial blue stain 
to see a distinct shift in migration of 150kDa IgG band. 
Desialylation of IgG was detected by running neuraminidase treated IgG on 4-
12% bis-Tris gel followed by transfer to a PVDF membrane.  This was 
followed by staining with biotynilated sambrucus niagra lectin and alkaline 
phosphatase conjugated streptavidin and detection using 5-bromo-4-chloro-3-
indolyl phosphate/nitro blue tetrazolium (BCIP/NPT) purple liquid substrate.  
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Chapter IV 
 
Discussion 
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N. meningitidis is gram-negative diplococcus that is often found 
colonizing the human upper respiratory tract of about 10% of humans in non-
epidemic settings.  Invasive disease, fortunately, is a rare occurrence relative 
to rates of colonization.  While most individuals are able to clear invading 
bacteria either through serum bactericidal activity or opsonophagocytosis, 
some persons remain susceptible to infection.  Two major reasons cited for 
susceptibility to meningococcal disease are 1) lack of natural bactericidal 
antibodies in serum against the bacteria and 2) complement deficiency.  In 
this thesis we have characterized an additional variable involved in 
modulation of natural immunity against N. meningitidis called ‘blocking 
antibodies’.  Blocking antibodies against meningoccci is not a new concept 
(163, 165, 166).  The novelty of the antibodies we have described is their 
existence in normal sera, in contrast to prior reports that describe blocking 
antibodies in convalescent or post-vaccine sera.  In this work we show that 
antibodies directed against specific outer membrane proteins Lip/H.8 and Laz 
of N. meningitidis can block the killing of the bacteria by otherwise bactericidal 
normal human serum or specific bactericidal antibodies directed against 
certain group B protein vaccine candidates.  
The phenomena of blocking antibodies has been described several 
decades ago and can influence immunity against a wide range of pathogenic 
bacteria such as Brucella abortus (153), B. melitensis (154) and 
Pseudomonas aeruginosa (155) (156). More recently, blocking antibodies 
have been demonstrated against non-typhoidal strains of Salmonella in HIV 
patients in Africa (199).  The first written account of blockings serum activity 
against arrange of gram negative bacteria including Neisseriae was provided 
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by Neisser and Wechsberg (196).  Another important study, demonstrating 
the of role blocking antibodies in inhibiting killing of the bacteria by otherwise 
bactericidal serum was provided by Lewis Thomas in 1943 (162).  This 
seminal study Thomas et al. is described in detail in the discussion of chapter 
II.  
Previous studies have shown that IgA and IgG against serogoup C 
(164, 165, 239, 240) and W-135 (166) can block complement mediated 
effector functions in post vaccinee serum.  However, in the studies mentioned 
above, the blocking antibodies identified were serogroup specific (i.e, directed 
against capsular polysaccharide following infection or immunization).  Unlike 
previous studies, the blocking IgG identified by us in normal human serum is 
not serogroup (capsule) specific and can block SBA against a serogroup A 
meningococcal strain.  At this point, we do not know whether the presence of 
these anti-H.8/Laz blocking antibodies predispose individuals to invasive 
meningococcal disease.  A study comparing the presence of anti-H.8 
antibodies in ‘acute’ sera (i.e., prior to the development of specific Ab against 
the invading strain) from persons with invasive disease with carefully matched 
controls during an epidemic of meningococcal disease may be one way to 
address this question.    
Low immunogenicity of the serogroup B polysialic acid capsule has 
prompted extensive research to identify outer membrane proteins as potential 
vaccine candidates.  Several genes encoding potential surface exposed 
protein antigens were identified (72, 73).  An extensively studied and 
promising vaccine candidate is called fHbp (previously referred to as 
GNA1870 or LP2086) (75, 150).  The ability of the blocking IgG to inhibit the 
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bactericidal activity of a monoclonal antibody against fHbp (Figure 2.5 A) is of 
considerable significance because it could identify individuals in whom the 
effectiveness of an fHbp-based vaccine may be blunted.  Another interesting 
observation was that the blocking IgG did not inhibit the bactericidal activity of 
a mAb against PorA (Figure 2.5 B), an abundantly expressed antigen.  PorA 
is the most immunogenic component both as a feature of natural immunity 
(106) and elicited by outer membrane vesicle based vaccines (191).  Outer 
membrane vesicle vaccines ‘tailor-made’ for epidemics, such as those seen in 
Cuba, Norway and New Zealand, have proven to be efficacious (14, 16, 241, 
242); the lack of an observed effect of anti-H.8 blocking IgG against anti-PorA 
Abs may be an advantage of these PorA-based vaccines. 
A limitation of outer membrane vesicle vaccines is their relatively 
narrow stain coverage that is dictated by the type of PorA molecule(s) in the 
vaccine preparation.  In order to circumvent this problem, one approach that 
has been tried is to delete PorA and over-express other more conserved 
proteins in the strain from which the vesicles are prepared.  In light of our 
findings, it is important to consider the attenuating effects of anti-H.8 Abs that 
may be elicited by H.8/Laz in the vesicle preparations (69-71).    
In the case of N. gonorhoeae, the specificity of blocking IgG is against 
the protein III (the homologue of Class 4 protein in N. meningitidis) (158).  The 
role of Rmp as a blocking target in N. meningitidis is still unresolved and at 
times conflicting.  One report suggests that mAbs directed against Rmp/Class 
4 proteins do not appear to have significant blocking activity against N. 
meningitidis (161).  In the same report, IgG purified from a recipient of the 
New Zealand phase II-9 vaccine trial a vaccinee whose serum reacted with 
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Rmp on an immunoblot was shown to posses blocking activity against 
serogroup B N. meningitidis strain H44/76 (161).  Interestingly, the IgG from 
this vaccinee was shown to be directed against an epitope 
‘’EPEPEPEPVVVV’ of Rmp, which, akin to the ‘AAEAP’ pentameric repeats 
of the H.8 antigen is Glu and Pro rich.  Munkley et al, showed that the same 
anti-Rmp mAb used by Rosenqvist et al directed against an epitope 
‘WKNAYFDK’ of the protein Rmp in meningococci could block the bactericidal 
activity of both mAbs and (otherwise bactericidal) serum (160).  However the 
blocking activity of the serum (against meningococci) identified in our study, is 
not directed against Rmp. We show that the blocking antibody against 
meningococci in normal human serum is directed against the pentapeptide 
‘AAEAP’ repeat containing H.8 domain of outer membrane proteins Lip (also 
called H.8) and Laz.  These data suggest that subtle differences in 
accessibility and/or relative spatial orientation of membrane antigens in the 
two closely related Neisserial species may account for differences in the 
specificity of blocking antibody.    
Surface components such as LOS, capsular polysaccharide and outer 
membrane proteins are important determinants of virulence of Neisseria spp 
(243-251).  These surface molecules are highly variable in terms of 
antigenicity and expression levels between different serogroups and strains of 
meningococci.  Efforts have focused on identifying a common antigenic 
determinant of pathogenicity among the different disease causing Neisseriae 
sp.  Conserved antigens that are shared among diverse strains are also 
attractive from the point of vaccine development.  The H.8 antigen was one of 
the first such identified antigens that was common to pathogenic Neisseriae 
106
  
(167).  However, the anti-H.8 antibody purified from humans or from mouse 
ascites was not bactericidal against Neiserriae, and further efforts to develop 
a H.8-based vaccine were abandoned (182). 
Pathogenic Neisseriae express two genes encoding the “H.8 antigen” 
(252). The first identified gene was lip which is almost entirely comprised of 
the H.8 domain (186, 253) and the second gene that coded for the H.8-like 
pentatpeptide repeats is the lipid modified azurin (Laz) (186) which comprises 
of a N-terminal non conserved H.8 like domain and a 127 amino acid azurin-
like domain.  The sequences of both Lip and Laz are highly conserved across 
all pathogenic strains of N. meningtidis and N. gonorrhoeae.  The fact that 
both proteins are found mostly in pathogenic neisseria (181) suggests an 
important function in virulence.   Here we show generation of complement 
blocking antibodies against H.8 antigens of both proteins in normal human 
serum.  It is also interesting that the ‘AAEAP’ pentameric repeats of the H.8 
domain of Lip is duplicated as Laz in only Neisseria spp; other pathogenic 
microbes express azurin but without the “H.8-like” domain.  The presence of 
these repeats must serve an important function and our work has shown that 
it contributes to immune evasion.   
As discussed above, the presence and role of blocking antibodies 
against N. meningitidis has been previously reported.  However, not much is 
known about the mechanism of action of these blocking antibodies.  Earlier 
work done with blocking antibodies against Rmp in N. gonorrhoeae has shed 
some light in this aspect. Joiner et al. have shown that this blocking IgG 
against gonococcal Rmp has complement fixing ability and inhibits killing of 
the bacteria by diverting the activated C3 to alternate sites on the bacterial 
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surface (159).  The blocking activity required only the F(ab)2 fragment of the 
anti-Rmp blocking IgG.  Earlier work done by the same group showed that the 
C5b-9 (MAC) forms higher molecular weight complexes in resistant 
gonococcal strains as compared to susceptible strains (193).  Collectively 
these data indicated that the blocking IgG against the Rmp protein of 
gonococci can itself fix complement itself but in an effete manner. 
In contrast to blocking anti-Rmp antibodies against N. gonorrhoeae that 
do not appear limit the amount of complement activation on the bacterial 
surface, but rather alter the site of C3 deposition and perhaps the ‘qualitative’ 
aspects of MAC insertion, we show that anti-H.8 blocking IgG against N. 
meningitidis acts by down-regulating classical pathway activation by otherwise 
bactericidal antibodies (Figure 3.5).  Also, this down-regulation of classical 
pathway activation and subsequent blocking activity required the N-linked 
oligosaccharide chains of the Fc portion of the blocking IgG (Figure 3.5 and 
3.4). This highlights an important difference between the two pathogenic 
members of the Neisseria genus not only in terms of the target of blocking 
antibody target, but also the mechanism of blocking.  
We further showed that the down-regulation of classical pathway by the 
anti-meningococcal blocking antibody that was evident when IgG-depleted 
serum was used as a complement source was not seen with purified 
complement components (C1 and C4) (Figure 3.8).  This indicated a role for a 
distinct serum factor to mediate the blocking effect.  Because of the 
requirement of Fc glycans in blocking, we hypothesized that a lectin in serum 
was the heat-stable molecule that participated in blocking.  A soluble lectin, 
MBL could be the serum factor required for blocking based on the observation 
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that the use of antibody-depleted MBL deficient serum as a complement 
source did not facilitate blocking of JAR 3 mediated killing by NK3 IgG. We 
\need more experiments to validate this possibility.  We speculate that MBL 
alone is unlikely to effect blocking because it has traditionally been regarded 
as an activator of complement.  However, in serum, MBL can be associated 
with a complement inhibitor called α2-macroglobulin (234) and we believe that 
it may be recruitment of α2-macroglobulin that results in blocking.  Prior work 
in our lab has shown that α2-macroglobulin and another complement inhibitor, 
C1 inhibitor, can also block the complement activating properties of MBL on 
the gonococal surface (230).  Experiments to address the role of α2-
macroglobulin and C1 inhibitor in the blocking initiated by human anti-H.8 
antibodies are underway.  Therefore we propose a hypothetical model in 
which the blocking IgG in normal human serum binds to the pentapeptide 
motifs of Lip and Laz in N. meningitidis and then recruits a MBL and  α2-
macroglobulin (and also possibly C1 inhibitor) that down-regulates the 
activation of the classical pathway by a proximate, and otherwise bactericidal, 
antibody (Figure 4).  
In order to bind to MBL, the N-linked glycans of the blocking IgG should 
terminate in either N-acetyl glucosamine (G0S0) (Figure 3.1 B) (207, 208, 
254) or in high mannose residues (215, 255, 256).  It is interesting that the 
murine mAb 2C3 directed against H.8 does not have blocking activity even 
though it is directed against similar or overlapping epitopes as the human anti-
H.8.  We believe that the glycan of the Fc of mAb 2C3 likely does not 
terminate in GlcNAc or Man and therefore may not bind to MBL.  Mass 
spectrometric analysis of the glycan of 2C3 is currently being perfomed by our 
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Figure 4. Proposed model for mechanism of action of blocking IgG.  Based on 
ourdata I propose the following model to explain blocking by human anti-H.8 antibodies. 
Blocking IgG (red antibodies) binds to H.8 antigen -containing outer membrane proteins, 
Lip (green) and Laz (orange) on the surface of meningococci. These blocking IgGs bind in 
close proximity to antibodies (black) that are otherwise bactericidal, which are directed 
against relatively sparsely distributed antigens (purple) such as factor H binding protein. 
We hypothesize that the blocking IgG probably then recruits MBL (possibly in complex with 
C1 inhibitor  , α2-macroglobulin) and prevents recruitment and activation of C1q by the 
bactericidal antibody, thereby blocking classical pathway activation and  meningococcal 
killing.
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collaborators at the National Research Council (Ottawa, Canada).   As a part 
of our future directions we will purify the anti-H.8 human blocking IgG from the 
blocking serum using immobilized purified recombinant Lip/H.8 for analysis of 
its Fc glycans.     
Another interesting point merits discussion.  On one hand the findings 
in Chapter II show that specific outer membrane proteins such as, Lip and Laz 
are targets for complement blocking IgGs against N. meningitidis.  On the 
other hand, the findings in Chapter III show that Fc N-linked glycosylation  (we 
speculate that they teminate in either GlcNAc or Man residues) of the blocking 
IgG may facilitate recruitment of MBL, which results in blocking activity.  A key 
question is which of the two factors a) the target antigen or b) IgG 
glycosylation is determines whether an anti-meningococcal IgG acts as a 
blocking antibody.  Stated differently, would a bactericidal antibody directed 
against bactericidal targets such as fHbp or Por1.7 function as a blocking 
antibody if their Fc N-linked glycans were to bind to MBL?  Studies to address 
this question will require characterization of the Fc glycans of these antibodies 
and modifying them (perhaps enzymatically) to resemble the glycans of anti- 
H.8 antibodies.  Alternatively, the same chimeric human-mouse (Fc-Fab) 
antibodies containing terminal Man residues can be generated by expressing 
them in Lec-1 CHO cells that lack the enzyme N-acetyl glucosaminyl 
transferase I (257) (ref. Figure 3.1 A, B).  These experiments will enable us to 
better understand how blocking occurs on the Neisseria but are beyond the 
scope of this thesis. 
Another possible explaination for why the blocking IgG is directed 
specifically against H.8 could be because the H.8-specific B cell clones in 
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these individuals are deficient in the enzyme galactosyl tranferase that adds 
the terminal Gal residues on to the N-linked glycans of IgG or the enzyme 
mannosidase that cleaves the excess mannose residues in the N-linked 
glycan prescursor chain during post translational modification in the golgi 
apparatus.  As a result the H.8 specific IgG terminates in GlcNac or high 
mannose residues, which might result in binding serum factors involved in 
blocking possibly MBL as our preliminary data indicates. 
Anti-H.8 blocking IgG in normal human serum may contribute to 
variations observed in natural immunity and susceptibility to N. meningitidis. 
This study also provides insight into the mechanism of this blocking activity 
and identifies an important biological role for antibody glycosylation and 
function.  Overall, the study provides important insights into natural immunity 
against N. meningitidis and has implications for vaccine develpment against 
meningococcal disease. 
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